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Summary
Prospective, longitudinal clinical studies in first-episode schizophrenia have become relatively 
commonplace over the past two decades or more and have provided a wealth of useful information 
regarding the clinical presentation, treatment, course and outcome of the illness.  However, there 
remain several unanswered questions. The majority of the studies have been conducted in upper 
income countries using often costly medication with heterogeneous samples. While the overall outcome 
of patients showed some progress, there is room for improvement yet. The overall aim of the 
dissertation was to study the clinical, biological and functional aspects of outcome in first episode 
schizophrenia in a resource constrained setting. 
We conducted a prospective, non-comparative, longitudinal study over 12 months assessing the efficacy 
and tolerability of a cost effective, long-acting injectable antipsychotic (LAI; flupenthixol decanoate) 
combined with an assertive monitoring program (AMP) among first-episode schizophrenia patients. 
Efficacy was measured by examining rates of response, remission and relapse, as well as quality of life 
and social and occupational functioning. Tolerability of our intervention was assessed by measuring 
extrapyramidal symptoms, and weight and metabolic changes. We also examined the evolution of 
treatment refractoriness by studying the rates of non-response, and other associated predictor and 
outcome features. 
We found high rates of acceptance and adherence to the LAI and AMP. Seventy percent of our patients 
completed the 12 months of treatment. Treatment response was achieved by 82% of the participants 
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and 60% achieved remission. Although 19% of our patients relapsed, the majority of the relapses were 
mild and did not require hospitalisation.  Patients experienced significant quality of life and social and 
occupational functioning improvements. We found mild rates of extrapyramidal effects, present in only 
a third of our cohort. The majority of the extrapyramidal effects were treated with anticholinergics or 
propranolol. Only 3% of our patients developed transient dyskinesia over the duration of the study. 
However, our cohort gained considerable weight, with statistically significant increases in BMI (p< .0001) 
and waist circumference (p=0.0006). Our cohort also experienced significant deleterious changes to 
their lipid profiles. Of particular concern was the increase in triglycerides (p=0.03) and a significant 
decrease in high density lipoprotein (p=0.005) leading to a 91% increase in the triglyceride/high density 
lipoprotein ratio. 
With regards to emerging treatment refractoriness, 12% of our patients met our pre-defined criteria for 
non-response. Non-responders were younger and at baseline showed more prominent disorganised 
symptoms, poorer social and occupational functioning, poorer quality of life for psychological, social and 
environmental domains, more prominent neurological soft signs (NSS), and lower BMI.  At endpoint the 
non-responders were characterised by higher levels of symptomatology in all domains; poorer 
functional outcome, poorer quality of life and greater cognitive impairments. They also had more 
prominent NSS and a lower BMI.  The strongest predictors of non-response were prominent baseline 
NSS and poor early (7 weeks) treatment response. 
In conclusion, the combination of an LAI with an AMP may be an effective and safe intervention in first-
episode schizophrenia, and may be particularly suitable for resource-constrained settings. The risk of 
weight gain and metabolic syndrome associated with antipsychotic treatment in first-episode 
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schizophrenia are not restricted to second generation antipsychotics and low-potency first-generation 
antipsychotics.  Ensuring effective treatment for first episode schizophrenia patients is a global problem, 
and likely to be under-recognised in LMICs. 
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Opsomming 
Oor die afgelope twee dekades het toenemend meer longitudinale kliniese studies, wat eerste episode 
skisofrenie bestudeer, die lig gesien.  Die studies het ‘n magdom van waardevolle inligtng oor die 
kliniese voorkoms, behandeling, verloop en uitkomste van die siekte opgelewer. Die meerderheid van 
die studies is egter in hoë inkomste ontwikkelde lande gedoen met pasiënte wat duur medikasie gebruik 
en hoofsaaklik in heterogene steekproewe. Alhoewel dit blyk uit hierdie studies dat daar oor die 
algemeen vordering gemaak word ten opsigte van die behandeling van pasiënte is daar steeds ‘n gebrek 
aan voldoende inligting oor die onderwerp veral in minder gegoede, ontwikkelende lande. Die 
oorhoofse doel van hierdie proefskrif is om binne ‘n hulpbron beperkte konteks die kliniese, biologiese 
en funksionele aspekte van pasiënt -uitkomste in eerste episode skisofrenie te ondersoek. 
Ons het ‘n longitudinale studie gedoen waarin ons die effektiwiteit en toleransie van ‘n enkele 
antipsigotiese medikasie vir 12 maande nagevors het. Die medikasie wat ons ondersoek het, is 
flupenthixol decanoate en word deur ‘n inspuiting gegee en die medikasie word dan geleidelik deur die 
liggaam geabsorbeer. As deel van die behandeling het ons pasiënte ook streng gemonitor. Ons het die 
effektiwiteit van die behandeling gemeet nagelang van hoe pasiënte reageer op die behandeling, 
hoeveel pasiënte in remissie gaan en terugval, en ook pasiënte se kwaliteit van lewe en hulle sosiale en 
beroepsfunksionering. Ons het toleransie gemeet nagelang van pasiënte se gewig en metaboliese 
verandering sowel as die voorkoms van medikasie geïnduseerde newe-effekte. Verder het ons pasiënte 
wat nie op medikasie gereageer het nie ondersoek sowel as die aspekte wat moontlik hiernee verband 
hou.  
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Ons het bevind dat die meerderheid van pasiënte hulle medikasie getrou geneem het en ook die streng 
monitering aanvaar het. Sewentig persent van die pasiënte het hulle 12 maande behandeling voltooi, 
82% het op die medikasie gereageer en 60% het in remissie ingegaan. Alhoewel 19% van die pasiënte 
teruggeval het, was dit nie so ernstig dat ons hulle moes hospitaliseer nie. Pasiënte het beduidende 
verbetering ten opsigte van hulle kwaliteit van lewe en sosiale en beroepsfunksionering getoon. Ons het 
slegs ‘n gematigde mate van medikasie geïnduseerde newe-effekte opgemerk en alleenlik by ‘n derde 
van die kohort.  In die meerderheid van gevalle het ons die newe-effekte met anticholinergics of 
propranolol behandel. Slegs 3% van die pasiënte het gedurende die verloop van 12 maande die kondisie 
transient dyskinesia ontwikkel. Ongelukkig het ons kohort geweldig baie gewig opgetel en die toename 
in pasiënte se BMI (p< .0001) en middellyf omtrek (p=0.0006) was statisties beduidend. Ons het ook 
bevind dat veranderinge in ons kohort se lipied profiele kommerwekkend is veral as in ag geneem word 
dat die toename in trigliseriede (p = 0,03) en die beduidende afname in die hoë digtheid lipoproteïen (p 
= 0,005) gelei het tot ‘n 91% verhoging in trigliseriede: hoë digtheid lipoproteïen verhouding. 
Ons het bevind dat 12% van ons pasiënte voldoen het aan ons voorafopgestelde kriteria vir pasiënte wat 
nie reageer op behandeling nie. Diegene wat nie op behandeling gereageer het nie was jonger by 
basislyn, het meer prominente ongeorganiseerde simptome, swakker sosiale en beroepsfunksionering, 
swakker kwaliteit van lewe (op sielkundige, sosiale en omgewingsgebiede), meer prominente 
neurologiese sagte tekens, en laer BMI gehad. By eindpunt het diegene wat nie gereageer op 
behandeling nie nie erger simptome, swakker funksionering, swakker kwaliteit van lewe en erger 
kognitiewe gebrekke getoon. Dit blyk dat die beste aanduiding dat pasiënte nie op behandeling sal 
reageer nie prominente neurologiese sagte tekens en swak reaksie op vroeë behandeling (gedurende 
die eerste 7 weke) is. 
7
Stellenbosch University  https://scholar.sun.ac.za
Ten slotte die kombinasie van medikasie, wat geleidelik deur die liggaam geabsorbeer word, en streng 
monitering is meer geskik vir lae-inkomste lande met beperkte hulprbronne. Die risiko vir 
gewigstoename en metaboliese sindroom  wat geaasosieer word met antipsigotiese behandeling in 
eerste episode skisforrenie is nie beperk tot tweede generasie antipsigotiese medikasie en lae dosisse 
eerste generasie antispsigotiese medikasie nie. Effektiewe behandeling vir eerste episode skisforrenie is 
‘n globale probleem en kry nie die nodige aandag in lae-inkomste lande nie. 
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Chapter 1 
Introduction 
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Introduction 
Clinical features of Schizophrenia 
Schizophrenia is a complex disorder with heterogeneous outcomes. According to the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) in order to make a diagnosis of 
schizophrenia, patients must have two or more of the following symptoms present for at least one 
month: delusions, hallucinations, disorganised speech, disorganised behaviour and negative 
symptoms (APA, 2013). However the majority of patients with schizophrenia have additional 
symptoms including depression, anxiety, cognitive, and motor symptoms.  
 
In contrast to the DSM-5 categorical approach, a dimensional approach hypothesizes that the 
symptoms of schizophrenia cluster together to form dimensions. These dimensions co-exist in 
patients with schizophrenia and are more likely to be correlated to aetiological, biological, and other 
clinical factors than the DSM-5 diagnosis (Andreasen et al., 2005). The majority of studies that used 
factor analysis to examine symptoms of schizophrenia using data obtained from the Positive and 
Negative Syndrome Scale (Kay et al., 1987) found that the symptoms of schizophrenia can be 
clustered into five dimensions (Potuzak et al., 2012; Wallwork et al., 2012). These dimensions are 
called positive, disorganised, negative, excitement and depression factors. 
 
The positive dimension consists of delusions and hallucinations, which have long been regarded as 
characteristic of schizophrenia. Delusions and hallucinations are easily identifiable and are most 
commonly associated with schizophrenia although they are not diagnostic, as they can be observed 
in other disorders. There is increasing evidence that positive symptoms may exist on a continuum 
with other experiences that are considered normal, such as odd or strange beliefs and occasional 
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auditory hallucinations. The latter experiences are quite common in the general population; in fact 
they are substantially more common than the positive psychotic symptoms in people with 
schizophrenia (van Os et al., 2009). There is no consistent evidence of an association between the 
positive dimension and functional outcome in people with schizophrenia. It has been suggested that 
the other symptom clusters have more influence on outcome than positive symptoms (Rabinowitz et 
al., 2012). 
 
The disorganised dimension is made up of disorganised speech and behaviour, conceptual 
disorganisation, difficulty in abstracting, and poor attention. Disorganised speech and behaviour 
have been traditionally regarded as positive symptoms; however they have been shown to form a 
separate cluster in factor analysis and are associated with different clinical and neurobiological 
features (Wallwork et al., 2012). Disorganised symptoms are associated with poor outcome in 
patients with schizophrenia in areas such as social functioning, work performance and social skills 
(Roche et al., 2014). This dimension has also been strongly associated with cognitive dysfunction, 
which may partially explain its ability to predict poor functional outcome (Ventura et al., 2009). 
 
The negative dimension includes affective flattening, alogia, asociality, avolition, and anhedonia. 
These symptoms have been labelled ‘negative’ symptoms due to the perceived loss of behaviours, 
interests, motivation and desires. Negative symptoms are a core feature of schizophrenia but they 
need to be differentiated from secondary negative symptoms. The latter may be as a result of 
comorbid depression, extra-pyramidal effects of antipsychotics, social exclusion, or a lack of 
environmental stimulation (Kirkpatrick et al., 2006). Recent studies have found that negative 
symptoms can be broadly divided into two clusters of symptoms: avolition and decreased emotional 
expression (APA, 2013; Millan et al., 2014). Avolition includes decreased motivation, asociality and 
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anticipatory anhedonia. Decreased emotional expression consists of diminished verbal and non-
verbal expression (facial expression, gestures and vocal intonations). Negative symptoms have been 
associated with poor functional outcomes and are not readily responsive to treatment however the 
association may also be mediated by other symptom clusters including social cognition (Millan et al., 
2014). 
 
The excitement dimension is made up of impulsivity, hostility, excitement and uncooperativeness. 
These symptoms represent an activation syndrome or behavioural disinhibition. They are particularly 
prominent during the active phase of the illness and they represent significant clinical challenges 
(Lindenmayer et al., 2004). They have also been associated with aggressive behaviour during 
hospitalisations (Colasanti et al., 2010). The depression dimension consists of anxiety, tension, 
depression, guilt feelings and somatic concerns. Depressive symptoms commonly occur not only as 
part of the so-called post-psychotic depression, but also during the acute phase of illness (Buckely et 
al., 2009; El Yajazi et al., 2002). The depressive and anxiety symptoms that are part of the acute 
phase are associated with good outcomes (Emsley et al., 1999), whilst persistent symptoms of 
depression have been associated with poor outcome and require more specific clinical investigation 
and treatment (Oosthuizen et al., 2006). 
 
Therefore it is evident that schizophrenia has enormous clinical variability in terms of symptom 
expression, which makes it a complex clinical disorder. It is also unknown to what degree the 
symptom domains influence outcome and whether this may be mediated by additional clinical 
features including social cognition (Millan et al., 2014). 
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First-episode schizophrenia 
The diagnosis of schizophrenia is most commonly made in young adults following their first episode 
of psychosis. The median age at onset of schizophrenia is between 25 and 35 years, with men having 
their onset in the mid-twenties and women in the mid-thirties (McGorry et al., 2011). Prospective, 
longitudinal clinical studies in first-episode schizophrenia have become relatively commonplace over 
the past two decades, and have provided a good deal of useful information regarding the clinical 
presentation, course and treatment of the illness.  
 
Studies that have used factor analysis to study symptom dimensions in first-episode schizophrenia 
have found interesting results. It appears that symptom expression during the first episode may be 
more complex than observed in chronic multi-episode schizophrenia patients. Three studies that 
used exploratory factor analyses found that symptoms were explained better by a seven factor, 
rather than five factor solution, with the separation of depression and anxiety dimensions and a new 
motor dimension (Emsley et al., 2003; Rapado-Castro et al., 2010; Wolthaus et al., 2000). 
Interestingly, the motor dimension was found at study entry in antipsychotic-naïve patients and 
consisted of mannerisms and posturing as well as motor retardation. These motor symptoms are 
part of the catatonic group of symptoms which were common prior to the antipsychotic treatment 
era. Catatonic symptoms have been found in up to 25% of antipsychotic-naïve patients and are 
associated with poor outcome (Cortese et al., 2005). Drake et al. (2003) followed up early psychosis 
patients for 18 months and found that the symptom dimensions at 18 months were similar to the 
symptom dimensions described in patients with chronic schizophrenia compared to the baseline 
data. In addition, models derived from 18 month data did not fit well with the baseline data. The 
emerging evidence therefore suggests that symptom dimensions may change with time making first-
episode schizophrenia patients more clinically heterogeneous than multiple episode patients. 
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Long-term course and outcome of schizophrenia 
The long-term course of schizophrenia is heterogeneous with patterns ranging from patients having 
a single episode to patients with a continuous unremitting course. Most patients with schizophrenia 
have a course that falls between the above extremes, with relapses and remissions. According to the 
DSM-5, the course of schizophrenia is described after examining both the cross-sectional as well as 
longitudinal features of the illness (APA, 2013). The cross-sectional ‘specifiers’ address the issue of 
whether a patient meets the criteria of being in the active phase and whether they are in partial or 
full remission.  The longitudinal pattern of the illness describes how the illness has progressed over 
the period of at least one year. The DSM-5 describes the course of schizophrenia in the following 
way:  
• First episode, currently in acute episode 
• First episode, currently in partial remission 
• First episode, currently in full remission 
• Multiple episodes, currently in acute episode 
• Multiple episodes, currently in partial remission 
• Multiple episodes, currently in full remission 
• Continuous 
• Unspecified 
Historically the course of schizophrenia has been described as the longitudinal pattern of the illness, 
whilst the outcome has been described as a cross-sectional measure. Therefore the outcome of 
patients with schizophrenia can be described at a single time point (e.g. at 5 years) (Gaebel and 
Frommann, 2000). One of the seminal studies on the long-term course of schizophrenia, the 
International Study of Schizophrenia, was conducted by the World Health Organization (WHO) 
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(Harrison et al., 2001). The study followed more than 1600 subjects with schizophrenia from 14 
culturally diverse treatment incident cohorts and four prevalence cohorts for up to 25 years. A Life 
Chart Schedule was used to assess the course of illness, including symptoms, treatment utilisation, 
residential status and work functioning. They found almost 30% of the patients had an acute onset 
of illness with multiple episodes of relapses and a good outcome, while 22% had an insidious onset 
of illness with multiple episodes of relapses and a good outcome. More than two-thirds (68%) of the 
patients with episodic illness had two or more episodes. Patients with an insidious onset of illness 
with continuous symptoms and poor outcome accounted for almost 15% of the sample. 
Interestingly, almost 15% of the patients that had initially been classified as having a continuous 
trajectory improved later and were reclassified as having a good outcome at the 15 year follow-up 
assessment. 
 
Various other studies on the long-term course of schizophrenia have been conducted however since 
they used inconsistent case definitions, different sampling methods and outcome measures 
comparison was difficult (Menezes et al., 2006). Jobe and Harrow (2005) reviewed studies that 
examined the long-term outcome of schizophrenia in North America including  studies that were at 
least 10 years in duration. Their results were similar to the WHO study, that there was heterogeneity 
in the course and outcome of patients with schizophrenia. Approximately 20% of the patients with 
schizophrenia had a single episode of illness with good outcome, and a further 20 – 30% of patients 
had multiple episodes with remissions and good outcome (Jobe and Harrow, 2005). The view that 
schizophrenia is a progressive illness with an invariably poor outcome has thus been challenged by 
well-designed long-term studies that show that patients with schizophrenia can experience periods 
of recovery and may even function well at work and socially. 
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Treatment of first-episode schizophrenia 
In the last two decades, there have been a large number of studies reporting on how best to treat 
first-episode schizophrenia patients. The prevailing approach is to treat with comprehensive multi-
element biopsychosocial treatment that is available in many early intervention centres around the 
world (McGorry, 2015). The guiding principle in the treatment of first-episode schizophrenia patients 
is that of the ‘critical period hypothesis’ (Birchwood et al., 1998). This hypothesis identified the first 
five years of illness as an important determinant on the trajectory of illness and intervention during 
this period is likely to have maximum impact on the future course. The three principles of treatment 
adopted by Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne, Australia and 
subsequently followed by many other early intervention services include: (i) early detection, (ii) 
comprehensive acute phase care, and (iii) recovery-focused continued care (McGorry, 2015). 
  
Early detection and treatment is the first component of early intervention services. This is aimed at 
reducing the time between the onset of psychotic symptoms and initiation of successful treatment, 
or duration of untreated psychosis (DUP). It is important to aim at reducing DUP as prolonged DUP 
has been shown to be an independent predictor of poor outcome in patients with first-episode 
schizophrenia (Marshal et al., 2005; Perkins et al., 2005). Interventions are aimed at increasing the 
awareness of mental illness in the general population and reducing treatment delays that are due to 
blockages in the pathways to care (Iyer et al., 2015). 
 
Comprehensive acute phase care often includes individual case management, family education and 
support, individual or group cognitive behavioural psychotherapy, and educational or vocational 
rehabilitation (Hughes et al., 2014; Iyer et al., 2015). A number of controlled trials have shown that 
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intensive early treatment of first-episode schizophrenia is more effective than standard care. For 
example, the large OPUS trial in Denmark showed that intensive treatment consisting of assertive 
community treatment, family intervention and social skills training had significant positive effects on 
psychotic symptoms, negative symptoms, secondary substance abuse, lower doses of antipsychotics, 
and higher satisfaction with treatment at the end of the two years (Petersen et al., 2005). However 
these positive outcomes were not observed at the five year follow up, except for fewer days in 
hospital and fewer patients in supported employment (Bertelsen et al., 2008).  A recent Cochrane 
systematic review that examined the effects of early detection, phase specific treatments and 
specialized early intervention teams found some support for early intervention, but further trials are 
desirable, as there is uncertainty in whether the treatment gains can be maintained beyond the 
early intervention treatment period (Marshall and Rathbone, 2011).  
 
Efficacy of antipsychotic treatment 
Although comprehensive, multiple psychosocial interventions are essential ingredients in early 
intervention services, antipsychotic treatment remains the cornerstone of the management of first-
episode schizophrenia. The majority of patients with first-episode schizophrenia have a robust 
response to antipsychotic treatment, unlike multi-episode patients (Robinson et al., 1999). Two 
recent meta-analyses studied the efficacy and side effects of antipsychotics in first-episode 
schizophrenia (Crossley et al., 2010; Zhang et al., 2012). The first study compared the efficacy of 
atypical versus typical antipsychotics in the treatment of early psychosis (Crossley et al., 2010). They 
included 15 randomised controlled trials that included a total of 2522 patients. They found no 
significant difference between atypical and typical antipsychotics in acute symptom response (at 3 
months) as the majority of patients with first-episode schizophrenia showed a good response to 
treatment. The second meta-analysis compared the efficacy and tolerability of individual second 
generation antipsychotics compared with first generation antipsychotics (Zhang et al., 2012). They 
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found that only olanzapine and amisulpride were superior to haloperidol in terms of short term 
symptom reduction and response to treatment. They also found that pooled second generation 
antipsychotics were similar to first generation antipsychotics in terms of treatment response. These 
two meta-analyses lend further weight to the principle that patients with first-episode schizophrenia 
respond robustly to most antipsychotics, irrespective of the drug class.  
 
Furthermore patients with first-episode schizophrenia require lower doses of antipsychotics for 
treatment of their symptoms and are more sensitive to the extrapyramidal effects of antipsychotics 
compared to chronic schizophrenia patients (Kapur et al., 1996; Oosthuizen et al., 2001). A seminal 
double-blind, randomised controlled study showed that low doses of haloperidol are as effective as 
higher doses in reducing psychotic symptoms in patients with first-episode schizophrenia 
(Oosthuizen et al., 2004). Low doses were better tolerated, with significantly fewer extrapyramidal 
symptoms, less utilisation of anticholinergic medication and lower levels of prolactin.  
 
Although short term response to antipsychotics is robust in patients with schizophrenia, longer term 
outcome of treatment is more important with regards to schizophrenia – a potentially life-long 
illness. Therefore studying remission in the treatment of patients with first-episode schizophrenia 
may be more meaningful. Remission is defined as the presence of mild, or no, ‘core’ psychotic 
symptoms for a period of six months (Andreasen et al., 2005). The core psychotic symptoms include 
delusions; unusual thought content; hallucinatory behaviour; conceptual disorganization; 
mannerisms/ posturing; blunted affect; passive/ apathetic social withdrawal; lack of spontaneity and 
flow of conversation. Five large studies have since been published that examined remission and its 
correlation in first-episode schizophrenia (see table 1 below).   
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The first study examined remission using data from a large multinational, randomized controlled trial 
comparing haloperidol with risperidone in early psychosis (Emsley et al. 2007). Four hundred and 
sixty two participants with schizophrenia, schizoaffective disorder, or schizophreniform disorder 
were treated with low doses of either haloperidol (mean modal dose of 2.9mg) or risperidone (mean 
modal dose of 3.3mg) for two to four years. Assessments were made using the Positive and Negative 
Symptom Scale (PANSS), Extrapyramidal Symptom Rating Scale (ESRS), and the Wisconsin Quality of 
Life Index. The authors found that 70% (n=323) of the patients met the cross-sectional remission 
criteria at some point during the trial. However, only 23.6% (n=109) were able maintain the low 
severity of symptoms for six months in order to achieve the remission criteria. Patients who 
achieved remission had greater overall symptom improvement, greater improvement in subjective 
quality of life, fewer relapses, and had a more favourable attitude towards their medication. The 
remitted patients also required lower doses of antipsychotic medication and had fewer 
extrapyramidal side effects. However, there was no difference in suicidality, cognition, body mass 
index, and whether patients were on risperidone or haloperidol. The authors noted that despite the 
good rate of initial response seen in first episode psychosis, the majority of patients failed to 
maintain the low severity of symptoms in order to achieve remission status (Emsley et al., 2007). 
 
The second study assessed the predictive validity of the remission criteria in first episode psychosis 
patients who had shown initial response to antipsychotics (Wunderink et al., 2007). The participants 
were enrolled into the study if they had positive psychotic symptom remission within their first year 
of treatment. They were then followed up for 18 months with symptoms measured using the PANSS, 
functioning measured using the Groningen Social Disabilities Schedule (GSDS), and quality of life 
measured by the World Health Organization Quality of Life Scale (WHOQOL-Bref). Of the 125 
patients included in the study, 60 (48%) patients achieved remission, whilst 65 (52%) failed to 
achieve remission. Patients who achieved remission had lower positive, negative, and 
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disorganization symptoms and better social functioning. However remission did not associate with a 
better quality of life.  
 
Addington and Addington (2008) examined the remission criteria in a secondary analysis of a first 
episode psychosis cohort from the Calgary Early Psychosis Program in Canada. They included data 
from 240 individuals with schizophrenia spectrum disorder or other psychotic disorder. Participants 
were given   comprehensive treatment for three years. Assessments were made using the PANSS, 
CDSS, the Quality of Life Scale (QLS), the Cannon-Spoor Premorbid Functioning Scale, and the Case 
Manager Rating Scale for Substance Use Disorder. The authors found that 36.7% (n=88) met the 
remission criteria; 19.6% (n=47) met the cross-sectional criteria at the last assessment; 20.4% (n=49) 
met the cross-sectional criteria at some time point but not at the last assessment (fluctuating 
group); and 23.3% (n=56) did not meet the criteria at any stage. The participants who achieved 
remission had lower levels of overall symptoms and a higher level of functioning at baseline and at 
the last assessment. They also had improved premorbid functioning and shorter DUP. They found no 
difference in the groups that achieved remission or the cross-sectional criteria only. The authors 
postulated that the latter group may well have met the remission criteria had the study continued 
for a longer period of time. The group that met the cross-sectional criteria at some time points 
(fluctuating group) had more severe positive psychotic symptoms at baseline and at end point. This 
group had higher levels of cannabis use at endpoint, possibly accounting for more severe positive 
psychotic symptoms at baseline (Addington and Addington, 2008). 
 
A secondary analysis from the European First-Episode Schizophrenia Trial, an open-treatment 
randomized trial compared the effectiveness of antipsychotics, and examined rates of remission 
(Boter et al., 2009). The primary aim of the trial was to compare the effectiveness of haloperidol 
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versus second generation antipsychotics in first episode psychosis patients. The investigators 
recruited 498 patients with schizophrenia, schizophreniform disorder or schizoaffective disorder. 
Patients were treated with low doses of haloperidol, amisulpride, olanzapine, quetiapine or 
ziprasidone in an open label randomized design for 12 months. Outcome assessments were made 
using the PANSS. Remission was achieved by 17% (n=18) of patients on haloperidol, 40% (n=42) on 
amisulpride, 41% (n=43) on olanzapine, 24% (n=25) on quetiapine, and 28% (n=23) on ziprasidone at 
12 months. Patients on amisulpride, olanzapine and ziprasidone had statistically significantly higher 
remission rates than patients on haloperidol. The study thus found that fewer patients on 
haloperidol achieved remission than some of the second generation antipsychotics (Boter et al., 
2009). 
 
The last study examined the longer-term outcome of first episode psychosis patients followed up in 
a specialized early psychosis program EPPIC in Melbourne, Australia (Henry et al. 2010).  723 
patients were treated in the program for at least two years. Study participants had been diagnosed 
with either non-affective psychosis (schizophrenia, schizophreniform disorder, schizoaffective 
disorder, delusional disorder, brief psychosis, and psychosis not otherwise specified) or affective 
psychosis (bipolar disorder and major depressive disorder with psychotic features) and were an 
epidemiologically representative cohort of first episode psychosis. Psychopathology was measured 
using the Brief Psychiatric Rating Scale, the Scale for Assessment of Negative Symptoms, and the 
Beck Depression Inventory. Quality of life was measured using the QLS, and functioning using the 
SOFAS and GAF scales. The follow up data was collected at approximately seven years after 
presentation. The investigators found that 36.8% (n=156) of the entire first episode psychosis 
patients met the cross-sectional remission criteria, whilst only 28.9% (n=72) of the patients with 
schizophrenia spectrum disorders met remission. The majority of the patients in remission (76.5%) 
had affective psychosis. Patients in remission also had higher mean scores for functioning and 
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quality of life (Henry et al. 2010).  Although the five studies used different methodologies and 
followed participants up for varying lengths of time, it is clear that the majority of patients with first-
episode schizophrenia did not reach remission when followed up for at least one year.  
 
Table 1: Remission in first-episode schizophrenia studies 
Study N Duration Treatment Remission 
Emsley et al., 
2007 462 2-4 years 
Haloperidol or 
Risperidone 23.6% 
Wunderink et 
al., 2007 125 1.5 years 
Risperidone, 
Olanzapine, 
Quetiapine, or 
Clozapine 
48% 
Addington 
and 
Addington, 
2008 
240 3 years 
Specialised 
early 
psychosis 
program 
36.7% 
Boter et al., 
2009 498 1 year 
Haloperidol, 
Amisulpride, 
Olanzapine, 
Quetiapine, or 
Ziprasidone 
Haloperidol = 17%; 
Amisulpride = 40%; Olanzapine 
= 41%; Quetiapine = 24%; 
Ziprasidone = 28% 
Henry et al., 
2010 723 7 years 
Specialised 
early 
psychosis 
program 
36.8% 
 
 
Tolerability of antipsychotic treatment 
The first experience of antipsychotics may have a lasting influence on subsequent engagement and 
adherence to antipsychotic medications therefore the choice of antipsychotic treatment in first-
episode schizophrenia patients is particularly important. Since there is little difference in the long-
term efficacy of antipsychotics, the choice of antipsychotic may be dependent on its adverse effect 
profile. Yet first-episode schizophrenia patients are more likely to experience adverse effects from 
antipsychotic treatment compared to multi-episode patients (McEvoy et al. 1999). This increased 
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sensitivity has traditionally been observed with first generation antipsychotics and their propensity 
to cause extrapyramidal side effects (EPS). Haddad et al. (2012) conducted a systematic review of 
randomised controlled trials in first-episode schizophrenia to examine the risk of extrapyramidal side 
effects of different antipsychotics. They found that second generation antipsychotics were less likely 
than first generation antipsychotics to cause EPS. However the majority of the studies used 
haloperidol as the comparator drug which is a high potency antipsychotic with leads to significantly 
higher rates of parkinsonism and akathisia. Patients treated with haloperidol had greater use of 
anticholinergic drugs as well as beta-blockers. They found very little difference in EPS rates between 
the second generation antipsychotics, which was possibly explained by the low doses used in the 
studies.  
 
With the increasing use of second generation antipsychotics, greater attention has shifted to the 
weight and metabolic adverse effects of antipsychotic. This is particularly important as patients with 
schizophrenia experience disproportionate rates of medical morbidity and mortality compared to 
the general population. Among causes of death, cardiovascular disease is responsible for as much as 
50% of the excess mortality associated with the diagnosis of schizophrenia. The suggested causes of 
cardiovascular disease within the schizophrenia population include lifestyle choices (i.e., smoking, 
inactivity, poor diet); substandard medical care; and iatrogenic contributions (e.g. antipsychotic-
induced weight gain) (Fan et al., 2013). 
 
Three systematic reviews have examined weight gain due to antipsychotics in first-episode 
schizophrenia patients. A systematic review of antipsychotic-induced weight gain in patients with 
schizophrenia treated by commonly prescribed antipsychotics (risperidone, olanzapine or 
haloperidol) found that patients with first-episode schizophrenia are at particularly high risk of 
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weight gain (Alverez-Jimenez et al., 2008). In fact, first-episode schizophrenia patients gained three 
to four times the amount of weight gained by multi-episode schizophrenia patients in both short 
term and long term studies. They concluded that young patients who had limited exposure to 
antipsychotics are particularly vulnerable to rapid and substantial weight gain.  
 
The second systematic review and meta-analysis that examined weight gain in antipsychotic-naïve 
patients found that weight gain and an increase in body mass index (BMI) were highly significant 
within the first few weeks of treatment (Tarricone et al., 2010). They found that patients gained on 
average 3.8 kg or their BMI increased by 1.2 points within 12 weeks of treatment. They also found 
that weight gain continues and does not plateau the longer patients are on treatment, although 
there were few studies that looked at long term treatment.  
 
Lastly, a recently published systematic review and meta-analysis examined the differential effects of 
antipsychotics on weight gain in first-episode psychosis patients (Tek et al., 2015). The authors 
conducted a meta-analysis of short and long term weight gain between placebo and antipsychotics. 
They found the overall mean weight gain difference between placebo and antipsychotics to be 3.22 
kg or 1.46 BMI points at or before 12 weeks. The only antipsychotic that did not cause significant 
weight gain in the short term was ziprasidone. The long term studies showed a mean weight gain of 
5.3 kg or 1.86 BMI points at 12 months. Interestingly, haloperidol and aripiprazole which are noted 
as weight neutral in chronic multi-episode studies were associated with significant weight gain in 
first-episode psychosis patients. 
 
Very few studies have examined other cardiometabolic effects of antipsychotics in first-episode 
schizophrenia (de Hert et al., 2011; Foley and Morley, 2011). Antipsychotic-induced weight gain is 
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associated with increases in blood glucose, fasting triglycerides and total cholesterol. Young patients 
are at particular risk of these cardiometabolic effects particularly from second generation 
antipsychotics (de Hert et al., 2011). A systematic review of cardiometabolic changes in first-episode 
schizophrenia patients found an increased risk of cardiovascular disease due to antipsychotics (Foley 
and Morley, 2011). Although there was limited data, the authors were able to separate individual 
antipsychotics’ cardiometabolic profiles but found no evidence for any class differences. And finally, 
a recent comprehensive meta-analysis of head-to-head trials that compared second generation to 
first generation antipsychotics in first-episode schizophrenia patients found that weight gain and 
glucose and lipid metabolism changes were not always consistent (Zhang et al., 2012). The 
antipsychotics that were associated with the most weight gain were not necessarily associated with 
greater increases in glucose and lipid parameters. 
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Early intervention in schizophrenia in developing countries: Focus on 
duration of untreated psychosis and remission as a treatment goal 
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duration of untreated psychosis and remission as a treatment goal 
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 Abstract 
 Early intervention services are based on the premise that untreated psychosis may have a deleterious effect on outcome, 
particularly in the early years of illness. The majority of the studies on duration of untreated psychosis have been conducted 
in developed countries; therefore this review focuses on publications from developing countries. We also review studies from 
developing countries that have been published following the Remission in Schizophrenia Working Group criteria. 
 The duration of untreated psychosis is longer in developing countries, and is also associated with poor outcome, whereas 
remission rates following treatment of fi rst-episode schizophrenia in developing countries appear to be higher than in 
developed countries. These two fi ndings strongly argue for the establishment of early intervention services for schizo-
phrenia in developing countries. 
 Introduction 
 Although there is a large body of research to under-
stand the causes and to improve the treatment of 
schizophrenia, it remains one of the most complex, 
burdensome and costly illnesses to date (Rossler 
et  al., 2005). In fact, schizophrenia is considered to 
be one of the most costly illnesses that psychiatrists 
treat (Rice, 1999). This has important implications 
for developing countries where most healthcare bud-
gets are under resourced. Yet there is now increasing 
evidence that early intervention services are cost-
effective. Resources diverted to early intervention 
programmes can have positive long-term effects on 
the outcome of schizophrenia (Chen et  al., 2008). 
There are hundreds of early intervention programmes 
being implemented around the world; however, the 
majority of these programmes are in developed coun-
tries. Developing countries in Africa, where the 
majority of the population is under the age of 
25 years, have progressed slowly in bringing early 
intervention services to the continent (Ndetei, 2008). 
Developing countries in Latin America have made 
more progress than Africa. There are now at least 
seven sites in Latin America where there is on-going 
research and services provided to people with the 
fi rst episode of psychosis; however, the majority of 
these services are in Brazil (Brietzke et  al., 2011). 
Recently Latin American researchers have called for 
more collaboration and increased efforts in expand-
ing their services. Developing countries in Asia have 
perhaps made the most progress in developing early 
intervention services, with some services mirroring 
the best models from developed countries (Iyer et  al., 
2010). However, there is also a call to expand these 
services to benefi t more people and to examine the 
best models to implement in resource-limited set-
tings (Keshavan et  al., 2010). 
 Early intervention services are based on the prem-
ise that untreated psychosis may have a deleterious 
effect on outcome, particularly in the early years of 
illness, and optimal intervention during the so called 
 ‘ critical period ’ will improve long-term outcome in 
schizophrenia (Birchwood et  al., 1998). We have thus 
focused this review on recent publications from 
developing countries examining duration of untreated 
psychosis and remission following treatment of the 
fi rst episode of psychosis. 
 Duration of untreated psychosis 
 The duration of untreated psychosis (DUP) is defi ned 
as the time from manifestation of the fi rst psychotic 
symptom to initiation of adequate antipsychotic 
treatment (Marshall et  al., 2005). The study of 
DUP and outcome has received increasing attention 
over the last two decades. This is largely due to the 
International Review of Psychiatry, October 2012; 24(5): 483–488
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establishment of early intervention services designed 
to shorten the delay in seeking treatment in people 
with early psychosis (McGorry et  al., 2008). The 
study of DUP has thus important implications 
as this may lead to improved understanding of 
the pathophysiology of schizophrenia. Furthermore, 
DUP is seen as a potentially modifi able predictor of 
outcome with important clinical implications, as out-
come could theoretically be improved by reducing 
DUP (Perkins et  al., 2005). There are, however, some 
authors who question the direction of the correlation 
between DUP and outcome; advancing that DUP 
may just be a marker of poor prognosis (Bosanac 
et  al., 2010; McGlashan, 1999). 
 Two infl uential systematic reviews published at 
approximately the same time concluded that DUP is 
an independent predictor of outcome in fi rst-episode 
psychosis (Marshall et  al., 2005; Perkins et  al., 2005). 
Marshall et  al. (2005) reviewed prospective studies 
of fi rst-episode psychosis cohorts that examined 
DUP and outcome. The authors included studies 
that restricted participants to schizophrenia-related 
disorders, assessed outcome blind to DUP status, 
achieved a follow-up rate of   50%, and used a stan-
dardized method to assess DUP. They found small 
or non-signifi cant correlations between DUP and 
outcome at baseline, but the correlations became 
signifi cant for most outcomes studied at 6- and 
12-month follow-up. At baseline there were correla-
tions between DUP and depression and anxiety 
symptoms, as well as quality of life. At six months 
there were signifi cant correlations between DUP and 
all symptom measures and overall functioning but 
not for quality of life. At twelve months there were 
signifi cant correlations between DUP and all symp-
tom measures, overall functioning and quality of life. 
At the two-year time point data was only available 
from two studies but also showed signifi cant correla-
tions between DUP and positive symptoms, overall 
functioning, and quality of life but not for negative 
symptoms or social functioning. The authors then 
examined the effect of premorbid adjustment on the 
relationship between DUP and outcome. They found 
that the association between DUP and particularly 
positive symptoms was robust even after adjusting 
for premorbid adjustment. Marshall et  al. (2005) 
concluded that there was convincing evidence of an 
association between DUP and outcome. 
 The second meta-analysis reviewed the relation-
ship between DUP and relapse risk, neurocognitive 
function, and brain morphology in fi rst-episode 
schizophrenia (Perkins et  al., 2005). They included 
43 studies that used quantitative measures of DUP; 
cross-sectional analyses of DUP and baseline 
symptoms, brain morphology, cognition, or func-
tional measures or prospective analyses of symp-
tom change; clinician rated instruments to measure 
psychopathology; and most of the subjects had a 
diagnosis of non-affective psychotic disorder. The 
authors found that shorter DUP was signifi cantly 
associated with greater response to antipsychotic 
treatment as measured by global psychopathology, 
positive symptoms and negative symptom severity, 
and global functional outcome. There was, however, 
no association between DUP and baseline cognition. 
DUP was associated with severity of negative symp-
toms at baseline, but not with positive symptoms and 
general psychopathology. There was no association 
between DUP and abnormalities in brain morphol-
ogy at baseline. And lastly, there was not enough 
evidence supporting the association between DUP 
and risk of relapse. The authors concluded that DUP 
was an independent predictor of treatment response 
and the extent of recovery from a fi rst-episode of 
schizophrenia (Perkins et  al., 2005). 
 The majority of the studies included in the above 
two systematic reviews were studies conducted in 
developed countries; however, a recent systematic 
review examined DUP and outcome in low and mid-
dle income (LAMI) countries (Farooq et  al., 2009). 
The review included studies that examined an asso-
ciation between DUP and improvement in symp-
toms, disability, or mortality, studies that used 
clinician rated instruments, and studies that met the 
criteria for a psychotic diagnosis according to DSM 
or ICD classifi cation systems. However, in an effort 
to include as many studies as possible, they did not 
exclude any studies on the basis of the quality of the 
measurement of DUP. They included 11 studies that 
were conducted in eight LAMI countries (Poland, 
Mexico, Turkey, Brazil, India, South Africa, China 
and Indonesia), out of a possible 152 countries. The 
authors found that longer DUP was negatively asso-
ciated with the degree of reduction of symptoms fol-
lowing treatment. There was a negative association 
between DUP and positive symptoms but DUP was 
not associated with negative symptoms at baseline. 
Longer DUP was associated with greater disability, 
but defi nite association between DUP and mortality 
could not be inferred from the available data. The 
authors concluded that although there were a small 
number of studies from LAMI countries, longer 
DUP was also associated with poorer response in 
LAMI countries. 
 In a related study, the same group then compared 
the fi ndings from above systematic review of DUP 
and outcome from LAMI countries to studies from 
high income countries and examined a possible asso-
ciation with gross domestic product (GDP) (Large 
et  al., 2008). The authors found the average mean 
DUP was signifi cantly longer in studies from LAMI 
countries compared to studies from high income 
countries (125.0 versus 63.4 weeks; p    0.012). 
Interestingly, however, studies from upper middle 
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income countries had a shorter DUP than studies 
from high income countries. In a subset of studies 
that examined DUP in patients with non-affective 
disorders who had received some treatment, the 
mean DUP from studies from the LAMI countries 
was also longer than similar studies from high income 
countries. The authors then examined the relation-
ship between DUP and GDP purchasing power in 
the studies from LAMI countries. They found a lin-
ear relationship between DUP and GDP, where 
DUP was reduced by 6 weeks for each increase of 
US $ 1,000 GDP purchasing power. However, this 
relationship did not hold true for data from high 
income countries. Nevertheless they concluded that 
long DUP in LAMI countries may be associated with 
low income rather than previously identifi ed factors 
such as lack of insight and insidious onset of illness, 
and family ’ s lack of understanding of need for treat-
ment. Long DUP in LAMI countries may be due to 
low income as well as the cost of treatment. 
 A number of studies conducted in LAMI countries 
have been published since the above systematic 
review. A recently published study from Iran exam-
ined DUP and pathways to care in a group of patients 
with fi rst-episode psychosis admitted to a psychiatric 
hospital (Sharifi  et  al., 2009). Their sample (n    91) 
included patients diagnosed with both affective and 
non-affective psychosis, and the majority of patients 
had bipolar disorder (40.6%). The mean DUP was 
found to be 52.0 weeks. The median DUP in patients 
with schizophrenia was much longer, though, close 
to two years. Interestingly they found that acute 
onset of illness and living in rural areas were predic-
tive of a shorter DUP. Another study examined DUP 
and pathways to care in patients with schizophrenia 
who presented for treatment in Karachi, Pakistan 
(Naqvi et  al., 2009). DUP was measured using the 
Interview for Retrospective Assessment of the Onset 
of Schizophrenia. They included 93 patients with 
schizophrenia. The mean DUP was 64 weeks. The 
DUP was not correlated with any demographic vari-
ables. Interestingly, the majority of patients presented 
to psychiatrists fi rst as the primary healthcare ser-
vices were not well developed. A recently published 
large epidemiological study of patients with fi rst-
episode psychosis in Sao Paulo, Brazil, found remark-
able results (Oliveira et  al., 2010). The investigators 
included 200 patients from a defi ned area of Sao Paulo 
who had made their fi rst contact with the mental 
health services, with most patients accessing the emer-
gency psychiatric services. The majority of the partici-
pants included in the study had non-affective 
psychosis (61%) and were living with their families 
(81%). The median DUP for their sample was sur-
prisingly short at 4.1 weeks. Following multivariate 
analyses, participants living alone were three times 
more likely to have a long DUP than those living with 
their families. The study concluded that the context 
in which patients live infl uences the DUP and its 
correlates. 
 Another recently published study examined clini-
cal features in a sample of fi rst-episode psychosis 
patients admitted to a psychiatric hospital in South 
Africa (Burns et  al., 2010). The investigators included 
54 patients with a diagnosis of schizophrenia, schizo-
phreniform disorder, or schizoaffective disorder. 
DUP was defi ned as the duration from onset of fi rst 
positive psychotic symptoms to hospitalization. The 
mean DUP was 35.08 weeks, with a median of 
6 weeks. Patients who attributed their illness to a 
spiritual or traditional cause had a signifi cantly lon-
ger DUP. Patients who visited a traditional healer 
prior to being hospitalized also had a longer DUP. 
The study was limited, however, by the small sample 
size which precluded multivariate analyses. Lastly, 
Thirthalli et  al. (2011) prospectively studied DUP 
and outcome in a cohort of antipsychotic na ï ve 
schizophrenia patients in the south of India. The 
authors included patients with schizophrenia or 
schizophreniform disorder diagnosed using a com-
puterized diagnostic interview schedule for DSM-IV. 
DUP was measured using the Interview for Retro-
spective Assessment of Onset of Schizophrenia. 
Symptom scores were measured using the Positive 
and Negative Symptom Scale (PANSS) and func-
tioning using the Social and Occupational Function-
ing Scale. Of the 119 patients included in the study, 
they were able to assess 93 patients at 1-year 
follow-up. The mean DUP was 90.2 weeks and was 
positively correlated to baseline total PANSS scores, 
total PANSS scores at 1-year follow-up and level of 
functioning. 
 There is considerable evidence that longer delays 
in initial treatment of schizophrenia is associated 
with a poorer outcome. However, what delays treat-
ment in LAMI countries is not well understood. 
Future research directions in the area of DUP should 
involve establishing methodologically sound studies 
in geographically diverse LAMI countries that 
explore cultural, economic, biological and demo-
graphic factors as well as health system barriers that 
may contribute to DUP. 
 Symptomatic remission as a measure 
of outcome 
 In an attempt to improve the study of outcome 
in schizophrenia, the Remission in Schizophrenia 
Working Group (RSWG) proposed a consensus def-
inition of remission in schizophrenia (Andreasen 
et  al., 2005). The RSWG published an operational set 
of criteria that defi ned remission as the presence of 
mild, or absence of, eight  ‘ core ’ psychotic symptoms 
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for a minimum period of 6 months. The  ‘ core ’ symp-
toms include delusions; unusual thought content; 
hallucinatory behaviour; conceptual disorganization; 
mannerisms/posturing; blunted affect; passive/
apathetic social withdrawal; lack of spontaneity and 
fl ow of conversation. The criteria can be assessed 
using the PANSS, the Brief Psychiatric Rating Scale 
(BPRS), and the Scale for Positive Symptoms/Scale 
for Negative Symptoms (SAPS/SANS). The thresh-
old of mild severity of symptoms means that the 
symptoms, if present, do not interfere with daily 
activities. The eight symptoms are considered to be 
the most diagnostically specifi c for schizophrenia and 
are most often utilized for hospitalization of patients 
with schizophrenia (van Os et  al., 2006). The time 
criteria of 6 months is an arbitrary cut-off; however, 
it is long enough to ensure that the improvement of 
symptoms is sustained and stable (van Os et  al., 
2006). 
 Prior to the publication of the RSWG criteria, 
studies that examined remission in fi rst-episode psy-
chosis cohorts used different remission defi nitions 
which led to a diverse variation of remission rates. 
Lieberman et  al. (2003) defi ned remission as 50% 
reduction in total BPRS scores from baseline with no 
more than a score of 3 on fi ve BPRS psychosis items 
and Clinical Global Impression Scale (CGI) of mild 
or less. However, there was no duration criterion as 
part of their remission criteria. Remission was the 
primary outcome in their double-blind randomized 
trial comparing chlorpromazine to clozapine in fi rst-
episode psychosis patients that were antipsychotic-
na ï ve. They found remission rates of approximately 
80% for both antipsychotics at the 1-year follow-up, 
whereas another double-blind randomized controlled 
trial of olanzapine versus haloperidol found remis-
sion rates of only 57.25% for olanzapine and 43.94% 
for haloperidol after 2 years (Green et  al., 2006). 
Their defi nition of remission was mild or less positive 
psychotic symptoms (P1, 2, 3, 5 and 6 on the PANSS) 
and a CGI of 3 or less for 4 weeks consecutively. A 
1-year follow-up of an epidemiological cohort of 
fi rst-episode psychosis in India found 50% remission 
rates (Saravanan et  al., 2010). The authors used a 
broad defi nition of remission that were no positive 
or negative psychotic symptoms for a period of 1 
month. A different epidemiological cohort study 
from Canada found higher remission rates (70%) at 
the end of 1-year follow-up (Malla et  al., 2002). 
Their defi nition of remission was absence of psy-
chotic symptoms (1 or 0 on all global items of the 
SAPS) for a period of 1 month. 
 The large variations in remission defi nitions made 
it diffi cult to compare fi ndings across studies, thus 
publication of the RSWG criteria has attracted 
considerable attention. Following the publication 
of the RSWG criteria, the fi rst published study to 
examine remission in fi rst-episode psychosis evalu-
ated symptom improvement patterns and variables 
that predicted remission (Emsley et  al., 2006). The 
authors followed up 57 participants with schizophre-
nia, schizoaffective disorder, or schizophreniform 
disorder who were treated with low doses of halo-
peridol over 2 years in South Africa. Psychopathol-
ogy was measured using the PANSS and Calgary 
Depression Scale for Schizophrenia (CDSS). The 
results showed that 70% (n    40) of the participants 
were able to meet the cross-sectional remission cri-
teria at some point during the study. However, only 
40% (n    23) were able to maintain the low levels of 
symptoms for 6 months in order to achieve the 
RSWG criteria. Only 19 patients maintained their 
remission status throughout the study. The mean 
remission time was 10 months. When studying the 
symptom improvement patterns, both remitted and 
non-remitted patients had signifi cant early improve-
ment (6 weeks) of symptoms, including the  ‘ core ’ 
psychotic symptoms, but only the remitted patients 
continued to have symptom improvement until the 
end of the study. The authors noted that although 
there were signifi cant differences in the overall level 
of symptoms between the remitted and non-remitted 
groups at end point, there was also considerable over-
lap, particularly with depressive symptoms (Emsley 
et  al., 2006). 
 A prospective study in fi rst-episode psychosis 
patients treated with a long-acting injectable antip-
sychotic showed remarkable rates of remission 
(Emsley et  al., 2008a). The investigators followed up 
50 patients with schizophrenia or schizophreniform 
disorder for two years. The participants were treated 
with risperidone long-acting injection. Assessments 
were made using the PANSS, CDSS, ESRS, the 
Social and Occupational Functioning Scale 
(SOFAS), and the Drug Attitude Inventory (DAI). 
The authors found that 64% (n    32) achieved 
remission at some point during the study, and inter-
estingly the majority of the patients (n    31) main-
tained their remission status throughout the study. 
Patients in remission showed more improvement in 
overall symptoms, excitement/hostility factor, 
depression/anxiety factor and insight scores. They 
also showed greater improvement in functioning, 
needed lower doses of risperidone long-acting injec-
tion with improvement in extrapyramidal symp-
toms. Patients in remission also remained longer in 
the study. The authors concluded that although 
fi rst-episode psychosis patients respond well to 
treatment they do not maintain their response into 
remission. However, in this study the majority of 
the patients maintained their remission status 
and this was postulated to be due to the assured 
antipsychotic delivery with a long-acting injectable 
antipsychotic (Emsley et  al., 2008a). 
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 Later Emsley et  al. (2008b) published a post hoc 
comparison of data drawn from two similar studies 
conducted at their centre. They used their site ’ s data 
from a large multinational, randomized controlled 
trial of fi rst-episode psychosis patients treated with 
oral haloperidol or risperidone (Schooler et  al., 2005) 
and data from the above-mentioned study where 
fi rst-episode psychosis patients were treated with ris-
peridone long-acting injection (Emsley et  al. 2008a). 
The two studies had similar methodologies, and 
patients came from the same catchment area and 
were treated by the same investigators, albeit a few 
years apart. The post hoc analysis included 47 patients 
from the fi rst study (oral group) and 50 patients in 
the injectable antipsychotic group. The demograph-
ics and baseline clinical features were similar between 
the groups, except the PANSS positive subscale was 
higher in the injectable antipsychotic group. Both 
groups showed good early (12 weeks) treatment 
response but patients in the injectable antipsychotic 
group continued to show symptomatic improvement 
until the study end point. The injectable antipsy-
chotic group had fewer discontinuations, more symp-
tomatic improvement, lower relapse rates amongst 
responders, and a higher remission rate (64% versus 
40.4%). The authors concluded that the study added 
to the evidence that assured antipsychotic delivery 
with a long-acting injectable antipsychotic leads to 
improved outcome in fi rst-episode psychosis patients 
(Emsley et  al., 2008b). 
 A recently published study from Turkey followed 
up fi rst-episode schizophrenia patients in a natural-
istic setting for a mean duration of 5 years (U ç ok 
et  al., 2011). The study reported on 93 patients who 
were followed up and assessed monthly for at least 
1 year. Psychopathology was measured using the 
BPRS, the SAPS and the SANS. Premorbid func-
tioning was assessed by the Premorbid Assessment 
Scale (PAS). During the fi rst 24 months follow-up, 
59.5% (n    56) met the RSWG criteria for remis-
sion. However, only 28% (n    16) of the patients in 
remission were able to maintain remission through-
out the study. Furthermore, another 16 patients who 
initially could not maintain remission were able to 
attain remission during the follow-up period (5 
years). The mean time to remission was 8.8 months. 
Patients in remission had a lower number of hospi-
talizations, shorter duration of hospitalizations and 
were more likely to be employed prior to baseline 
and during the follow-up period. Therefore, remis-
sion following fi rst-episode schizophrenia is achiev-
able even with long follow-up periods and is an 
important indicator of functioning (U ç ok et  al., 
2011). A 6-year follow-up study of patients with 
schizophrenia living in the rural areas of Bali, Indo-
nesia, was recently published (Kurihara et  al., 
2011a). The authors assessed patients who had been 
previously identifi ed in the community as having 
schizophreniform disorder or schizophrenia at 5.5 
years and 6 years later. Of the 37 patients at the 
6-year follow-up, only 10 (27%) met the RSWG 
criteria for remission. Interestingly all 10 patients in 
remission also met their criteria for functional remis-
sion. Low negative symptoms scores at baseline and 
receipt of psychiatric treatment for more than half 
the follow-up period were signifi cant independent 
predictors of remission. The same group then pub-
lished a long-term follow-up of a group of hospital-
ized fi rst-episode schizophrenia patients in Bali, 
Indonesia (Kurihara et  al., 2011b). At the 17-year 
follow-up they were able to assess 43 out of the 
original 59 patients. Fifteen patients (25.4%) had 
died and one patient refused to be assessed. Nine-
teen patients (32.2%) met the RSWG criteria for 
remission. Interestingly the only predictor of remis-
sion was short DUP (less than 12 months) at the 
baseline assessment. 
 Conclusions 
 The well replicated fi nding of an association between 
longer DUP and poorer long-term outcome in 
developed countries also appears to holds true for 
LAMI countries despite the relatively small number 
and considerable heterogeneity of LAMI studies. 
Although DUP may depend on a number of factors, 
it is cause for concern that the average mean DUP 
in studies from LAMI countries is signifi cantly lon-
ger compared to studies from high income countries. 
The recently published studies also show that local 
context, particularly how the health services have 
been organized, infl uence access to healthcare and 
the DUP. It is also interesting that a number of 
studies found correlations between a shorter DUP 
and living with family members. Further, studies of 
outcome in early psychosis in LAMI countries indi-
cate high rates of remission following treatment. 
However there have been very few studies from 
developing countries that have measured outcome 
using the RSWG criteria. 
 These two observations argue strongly for the 
establishment of early intervention services for 
schizophrenia in these countries. While such services 
would require additional costs, improved outcomes 
may lessen the overall burden imposed by this illness 
on healthcare resources. In any event, apart from 
fi nancial considerations, there is the ethical obliga-
tion to provide the best possible care for our 
patients. 
 Declaration of interest: The authors report no 
confl icts of interest. The authors alone are respon-
sible for the content and writing of the paper. 
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Abstract
Aim: To assess the feasibility and
effectiveness of depot antipsycho-
tic (flupenthixol decanoate) com-
bined with an assertive monitoring
programme (AMP) in first-episode
schizophrenia.
Methods: This was a prospective,
non-comparative, longitudinal study
conducted over 12 months assessing
patient acceptance, adherence,
outcome in domains of psychopa-
thology, functionality and quality of
life, and tolerability.
Results: Of 207 participants, 149
(72%) completed 12 months of treat-
ment. Acceptance of and adherence
to depot was good. Treatment re-
sponse was achieved by 170 (82%)
participants and remission by 124
(60%). Thirty-three (19%) responders
relapsed and 10 (5%) participants met
a priori criteria for treatment resist-
ance. Treatment was generally well
tolerated.
Conclusions: Combination of depot
antipsychotic with an AMPmay be an
effective and safe intervention in early
phases of schizophrenia, and may be
particularly suitable for resource-
constrained settings.
Key words: antipsychotic, developing country, psychotic disorder,
schizophrenia.
INTRODUCTION
As a major contributor to disability-adjusted life
years globally,1 schizophrenia imposes a dispropor-
tionate emotional and financial burden on affected
individuals, their families and carers, health-care
systems and society.2 The situation is particularly
severe in low and middle income countries (LMICs)
where poverty exacerbates the burden,3 and where
the treatment gap for severe mental disorders is
Early Intervention in Psychiatry 2014; ••: ••–•• doi:10.1111/eip.12141
bs_bs_banner
First Impact Factor released in June 2010
and now listed in MEDLINE!
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enormous.4 Whereas part of this gap is due to
patients not seeking biomedical help,5 another likely
major contributor is non-adherence to prescribed
treatment, particularly in theperiod after first hospi-
talization.6 Depot antipsychotics were developed
in the 1960s to address the adherence problem
in schizophrenia. However, they were typically
reserved for patients with demonstrated poor treat-
ment adherence or multiple relapses – that is, those
who had been ill formany years.7 Their greatest ben-
efits may in fact be observed early in the illness by
improving adherence and preventing accruingmor-
bidity.8 On their own, depots do not necessarily
improve adherence, as patients may still default on
treatment. Their great advantage, however, is that
they make adherence explicit, thereby permitting
timeous intervention for thoseat riskof relapse.With
these considerations in mind, we developed an
intervention comprising the use of a conventional
depot antipsychotic with the following innovations:
(i) targeting the early phase of illness; (ii) initiating
depot treatment in the acute treatment phase to
reduce the risk of disengagement between acute and
maintenance phase treatment; (iii) using the lowest
possible dose tominimize tolerability problems; and
(iv) most importantly, exploiting the overt nature of
adherencewith depot bymeans of a simple assertive
monitoringprogramme (AMP) suitable for resource-
constrained settings.This study explored the accept-
ability, feasibility, efficacy and tolerability of this
intervention in a collaborative two-site study con-
ducted in Cape Town, South Africa, and Ibadan,
Nigeria.
METHODS
This was an exploratory, non-comparative study
assessing flexible doses of a conventional depot
antipsychotic (flupenthixol decanoate) combined
with an AMP as first-line treatment in first-episode
schizophrenia. We report here the 12-month
outcome results. Approval to conduct the study was
obtained from the Stellenbosch University Faculty
of Medicine and Health Sciences Human Research
Ethics Committee and the University of Ibadan/
University College Hospital Ethics Committee. The
study was conducted in accordance with the Inter-
national Conference on Harmonization guidelines
on good clinical practice.9
Participants
Subjects were recruited fromfirst referrals to psychi-
atric hospitals and community clinics within our
catchment areas in Cape Town and Ibadan between
April 2007 and March 2011. Patients and/or their
legal guardians provided written, informed consent.
Eligible participants were men and women, in- or
outpatients, aged 16–45 years, with a first episode of
psychosis meeting DSM-IV10 (Diagnostic and Statis-
tical Manual of Mental Disorders, Fourth Edition)
diagnostic criteria for schizophreniform disorder,
schizophrenia or schizoaffective disorder. Patients
were excluded if they had, during their lifetime,
been exposed to greater than 4 weeks of antipsy-
chotic medication, been treated with a depot antip-
sychotic, and had a serious or unstable medical
condition, mental retardation or current substance
abuse.
Assessments
At baseline we obtained demographic information,
psychiatric and collateral history, and records of
previous and current treatment. All participants
were assessed with the Structured Clinical Interview
for DSM-IV (SCID).11 Efficacy assessments com-
prised Positive and Negative Syndrome Scale
(PANSS),12 Clinical Global Impression (CGI) scale,13
Calgary Depression Scale for Schizophrenia
(CDSS),14 Social and Occupational Functioning
Assessment Scale (SOFAS)10 and the World Health
Organization Quality of Life-BREF (WHOQOL-
BREF) Scale.15 Duration of untreated psychosis
(DUP) was estimated from the onset of continuous
positive psychotic symptoms to initiation of
adequate treatment. Adequate treatment was
defined as the start of structured treatment with
antipsychotic medication.16 Subjects underwent
physical examination. Tolerability measures com-
prised adverse event (AE) reporting, Extrapyramidal
Symptom Rating Scale (ESRS),17 weight, height and
waist circumference. There were nine scheduled
visits over the 12-month period – at baseline, weeks
1, 2, 4 and 6 and at months 3, 6, 9 and 12. Unsched-
uled visits took place at the investigators’ discretion.
Subjects were evaluated with the PANSS, CGI, CDSS
and ESRS at each scheduled visit and with the
SOFAS and WHOQOL-BREF at 0, 6 and 12 months.
Investigators were trained in the use of the assess-
ment instruments and underwent interrater reli-
ability (IRR) testing prior to commencing the study.
The IRR was >75% for all scales.
Interventions
Medication
There was a washout phase of up to 7 days
during which all psychotropic medications were
Depot antipsychotic in early psychosis
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discontinued. Patients were treated with oral
flupenthixol 0.5–4 mg day–1 for 1 week prior to the
first flupenthixol decanoate dose to test for hyper-
sensitivity. The starting dose of flupenthixol
decanoate was 10 mg two weekly deep intramuscu-
lar injection (IMI), with six weekly increments of
10 mg two weekly IMI permitted, to a maximum of
30 mg two weekly IMI. The starting dose could be
reduced to 5 mg two weekly IMI in patients younger
than 18 years. In the event of additional antipsy-
chotic medication being required between visits,
oral flupenthixol was allowed at the discretion of
the investigator. Investigators were encouraged
not to increase the dose of flupenthixol decanoate
too rapidly, but rather prescribe lorazepam up to
12 mg day–1 for agitation during the acute phase
of the study, and thereafter up to 4 mg day–1. Other
permitted concomitant medications included
orphenadrine, trihexyphenidyl or biperiden for
parkinsonismor dystonia; propranolol for akathisia;
and antidepressants and medication for medical
conditions at the investigators’ discretion. Other
antipsychotics, mood stabilizers and psychos-
timulants were not permitted.
AMP
The study coordinators (mental health nurses) were
responsible for the AMP. They established good
relations with patients and carers and provided
psychoeducation with a structured approach em-
phasizing the need for continuous treatment. Study
participation was by means of a shared decision-
making process, involving family members where
possible. A register was kept with patient appoint-
ment dates. Reminders were sent out by mobile
phone text messaging. In the event of a missed
appointment, patientsor their carerswerecontacted
telephonically by the mental health nurse and
encouraged to come in for treatment.Where neces-
sary, community health-care nurses were requested
tocontact thepatient, and if all else failed, toconduct
home visits.
Data analysis and outcome measures
We recorded all of the data in electronic case record
forms. All entries were double-checked. Analyses
were conducted using Statistica 11 (StatSoft, Inc)
software. We used descriptive statistics, reporting
means (SD). For efficacy and tolerability evalu-
ations, we compared changes in scores from base-
line to 12 months (per protocol population) and to
end-point (intent to treat population, last observa-
tion carried forward) by Wilcoxon signed rank two-
tailed test. Treatment response was defined as ≥50%
reduction of PANSS total scores from baseline,
calculated as (baseline score – end-point score)/
baseline score – 30.18 We defined remission accord-
ing to Remission in Schizophrenia Work Group
criteria.19 We calculated relapse rates for those
patients who had achieved a treatment response
using relapse criteria adapted from those of
Csernansky et al.20 comprising any of: (i) 25%
increase in PANSS total score from the previous
visit; (ii) an increase of 10 points if the PANSS total
score was less than 40; or (iii) a score of 6 (‘much
worse’) or 7 (‘very much worse’) on the CGI scale.
Treatment resistancewas defined a priori as any one
of: (i) study discontinuation due to poor response as
judged by the investigator; (ii) end-point treatment
response <20%; or (iii) end-point PANSS total score
>70. For (ii) and (iii) criteria, patients were only con-
sidered treatment resistant if they had completed at
least 3 months of treatment, and had not experi-
enced a relapse. Adherence to depot was calculated
as the percentage of actual injections received
divided by the prescribed number of injections. To
investigate predictors of remission and relapse, we
conducted logistic regression using the following
selected demographic and baseline clinical vari-
ables: age, gender, highest educational level, family
history of schizophrenia, DSM-IV diagnosis, DUP,
substance abuse in the past 3 months, PANSS
positive/negative and general psychopathology
subscale scores, CDSS total score, SOFAS score and
WHOQOL-BREF transformed scores for domains
1–4.
RESULTS
We evaluated 328 patients, 91 of whom were not
eligible, 15 declined participation, and 5 absconded
prior to enrolment. A further 10 patients were
excluded as they no longer met the inclusion/
exclusion criteria before receiving study treatment.
Therefore, 207 participants were included in the
analyses – 126 patients from Cape Town and 81
from Ibadan. The majority of the patients had
schizophrenia (149; 72%); 54 (26%) patients had
schizophreniform disorder; and 4 (2%) patients
had schizoaffective disorder. Table 1 presents the
demographic and baseline clinical details of the
sample.
Feasibility, acceptability, adherence
Each study coordinator was able to effectively
manage a caseload of up to 70 patients with the
AMP. Acceptance of depot treatment was good. Two
B. Chiliza et al.
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patients refused study participation because of fear
of needles, and no injection site-related AEs were
reported. All but one of our patients received their
flupenthixol depot injections at two weekly inter-
vals. (One patient switched to four weekly injections
from week 40 to week 48 due to work commit-
ments.) Our window period for the biweekly injec-
tions was 3 days. Although patients occasionally
went beyond this period, overall adherence was
good. One hundred and ninety-two (93%) patients
received 100% of the prescribed depot injections
(including patients who discontinued early), and
the other 15 (7%) received a mean of 84% of the
injections. (Fourteen patients at the Cape Town site
received long-acting risperidone injection in place
of flupenthixol depot injection for the first 12 weeks
of the study as part of a sub-study. They were sub-
sequently switched to flupenthixol decanoate.) The
mean (SD) biweekly dose of flupenthixol decanoate
was 11.6 (4.6) mg at 12 months for the per protocol
patients and 11.5 (4.3) mg at end-point. Regarding
concomitant medication, 109 (52%) patients were
prescribed benzodiazepines and 31 (15%) antide-
pressants.
Efficacy
One hundred and forty-nine (72%) participants
completed the 12 months of treatment. For the 58
(28%) who discontinued, reasons given were lost to
follow up (n = 19, 9%), consent withdrawal (n = 16,
8%), poor response as judged by the investigator
(n = 9, 4%), relocation (n = 7, 3%), medication side
effects (n = 3, 1%), change of diagnosis (to bipolar
disorder) (n = 2, 1%), persistent substance abuse
(n = 1, 1%) and others (n = 2, 1%). Forty-seven (23%)
patients were hospitalized at the start of the study,
and eight (4%) required hospitalization during the
course of the study, for worsening of psychosis
(n = 2, 1%), hostility and aggression (n = 2, 1%),
attempted suicide (n = 1, 1%), severe depression
(n = 1, 1%), victim of assault (n = 1, 1%) and general
medical condition (n = 1, 1%).
Treatment response (≥50% PANSS total score
improvement) was achieved at some point by 170
(82%) of the 207 participants. Of the patients who
responded, 33 (19%) relapsed according to our
broadly defined criteria.20 Most of the relapses were
mild and did not require hospitalization. One
hundred and twenty-eight (62%) patients met
cross-sectional remission criteria and 124 (60%)
achieved full remission (i.e. maintained for 6
months)19 at 12 months. Ten (5%) participants met
our a priori criteria for treatment resistance. For the
logistic regression analyses, a lower baseline PANSS
negative subscale score (odds ratio (OR) 1.2, 95%
confidence interval (CI) 0.7–1.0, P = 0.009) and
lower baseline CDSS score (OR 1.3, 95% CI 0.53–
0.97, P = 0.01) significantly predicted remission,
and female gender (OR 4.4, 95% CI 3.1–5.8,
P = 0.03) predicted relapse.
Table 2 provides details of key efficacy and toler-
ability measures at baseline, 12 months (per proto-
col) and end-point.
TABLE 1. Demographic details of the 207 participants
Age, years: mean (SD) 25.87 (6.92)
Gender, n (%)
Male 137 (66)
Female 70 (34)
Ethnicity, n (%)
Black African 99 (48)
Mixed ancestry 98 (47)
White 10 (5)
Marital status, n (%)
Single 164 (79)
Married 30 (14)
Divorced 10 (5)
Widowed 2 (1)
Cohabiting 1 (1)
Employment status, n (%)
Unemployed 177 (86)
Full-time employment 25 (12)
Casual employment 5 (2)
Diagnosis, n (%)
Paranoid schizophrenia 78 (38)
Undifferentiated schizophrenia 44 (21)
Disorganized schizophrenia 25 (12)
Catatonic schizophrenia 2 (1)
Schizophreniform disorder 54 (26)
Schizoaffective disorder 4 (2)
Family history of schizophrenia, n (%)†
Yes 81 (40)
No 123 (60)
Duration of untreated psychosis, weeks:
mean (SD)
78.38 (147.65)
Duration of untreated illness, weeks:
mean (SD)
120.09 (154.06)
Lifetime history of illicit substance abuse,
n (%)‡
Yes 80 (41)
No 116 (59)
Previous exposure to antipsychotic
medication, n (%)
Yes 61 (29)
No 146 (71)
Duration of antipsychotic exposure for
the 61 subjects, days: mean (SD)
10.50 (7.10)
Hospitalized at start of study, n (%)
Yes 47 (23)
No 160 (77)
†N = 204.
‡N = 196.
Depot antipsychotic in early psychosis
4 © 2014 Wiley Publishing Asia Pty Ltd
43
Stellenbosch University  https://scholar.sun.ac.za
Tolerability and safety
Extrapyramidal symptoms
Mean (SD) ESRS total and subscale change scores
frombaseline tomaximum scores showed some sig-
nificant increases, particularly for parkinsonism
and akathisia subscales (Table 2). Sixty eight (33%)
patients reported 132 Extrapyramidal symptoms-
related AEs (akathisia [n = 26, 13%], parkinsonism
[n = 28, 14%], stiffness [n = 18, 9%], tremor [n = 22,
11%], dystonia [n = 20, 10%], dyskinesia [n = 10, 5%]
and unspecified [n = 9, 4%]). Most of these AEs were
mild. Six (3%) patients developed mild, transient
dyskinesia. Sixty-nine (33%) patients were pre-
scribed anticholinergics or propranolol for
extrapyramidal symptoms.
Body mass
There were substantial increases in weight, body
mass index and waist circumference (Table 2). One
hundred and fifteen (56%) patients had weight gain
of 7% or greater. Two patients (1%) had diabetes
mellitus prior to study entry but there were no
emergent cases reported during the study.
The following additional AEs were reported in
>10% of the participants: depression (n = 68, 33%),
excitement (n = 27, 13%) and anxiety (n = 21, 10%).
There was one (0.5%) attempted suicide.
DISCUSSION
Feasibility, acceptability, adherence
The results of this study suggest that depot antipsy-
chotic combined with an AMP is feasible, and may
be an effective intervention in first-episode schizo-
phrenia in resource-constrained settings. The sim-
plicity of the AMP means that community health-
care providers can deliver it without the necessity
for extensive training, and it permits effective man-
agement of large caseloads simultaneously. This
approach enables a large proportion of the care of
patients with schizophrenia to be provided by
primary care workers under the supervision of
general physicians and mental health specialists,
wherever available. This task shifting may greatly
improve access to effective treatment. Shared
decision-making contributed to good patient and
carer acceptance of injections. In this regard, depot
TABLE 2. Mean (SD) efficacy and tolerability scores at baseline, 12 months and end-point
Baseline
(n = 207)
12 months†
(n = 149)
P End-point‡
(n = 207)
P
Positive and negative symptom scores
Total 86.5 (19.2) 42.5 (11.4) <0.0001 48.8 (17.2) <0.0001
Positive subscale 22.3 (5.8) 8.8 (3.0) <0.0001 11.0 (5.4) <0.0001
Negative subscale 23.2 (8.1) 12.2 (4.7) <0.0001 13.7 (6.0) <0.0001
General psychopathology subscale 40.9 (10.1) 21.5 (5.7) <0.0001 24.0 (8.1) <0.0001
Clinical global impressions
Severity 5.1 (0.8) 2.3 (0.9) <0.0001 2.7 (1.2) <0.0001
Improvement – 1.4 (0.6) – –
Calgary depression scale for schizophrenia 2.8 (3.9) 1.4 (3.0) <0.0001 1.4 (2.9) <0.0001
Social and occupational functioning scale 43.9 (11.9) 70.1 (13.3) <0.0001 63.7 (16.6) <0.0001
WHO Quality of Life-BREF Scale
Domain 1 transformed score 12.0 (2.4) 13.0 (2.3) <0.0001 12.7 (2.4) <0.0001
Domain 2 transformed score 12.6 (2.7) 13.4 (2.1) <0.0001 13.2 (2.3) <0.0001
Domain 3 transformed score 10.7 (4.3) 12.6 (3.9) <0.0001 12.3 (4.1) <0.0001
Domain 4 transformed score 11.5 (3.1) 13.7 (2.4) <0.0001 13.3 (2.9) <0.0001
Extrapyramidal Symptom Rating Scale§
Total 2.0 (4.7) 2.1 (4.8)§ 0.7
Questionnaire 0.5 (1.2) 2 (2.4)§ <0.0001
Parkinsonism 1.2 (3.2) 3.6 (5.6)§ <0.0001
Dystonia 0 (0) 0.1 (0.8)§ 0.03
Dyskinesia 0.1 (0.4) 0.2 (0.8)§ 0.01
Akathisia 0.07 (0.3) 0.5 (1.1) <0.0001
Weight (kg) 58.4 (11.8) 66.8 (13.7) <0.0001 65.2 (13.8) <0.0001
Body mass index (kg m–2) 21.0 (3.6) 24.1 (4.8) <0.0001 23.4 (4.7) <0.0001
Waist circumference (cm) 76.8 (10.5) 84.5 (12.4) <0.0001 82.2 (12.2) <0.0001
†Per protocol.
‡Intention to treat, last observation carried forward.
§Highest score at any visit.
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antipsychotics may be particularly suited to LMICs,
where attitudes towards injectable medications
may be more favourable.21 Additionally, the psy-
choeducation and shared decision-making compo-
nents of our AMP by trained mental health nurses
are likely to have led to a higher rate of acceptance of
the depot antipsychotic.
Study retention rates were high and adherence
good – an important finding given that non-
adherence is a major preventable cause of morbid-
ity. Although non-adherence prevalence rates of
41–49% have been reported in higher income coun-
tries,22 the rates are likely to be even higher in LMICs
where factors such as lack of education, poor under-
standing of medical disease models and inacces-
sibility of services prevail – for example, studies in
Nigeria and South Africa show that only about 1
in 5 of such persons receive any treatment in a
12-month period.4
Efficacy
As would be anticipated in a first-episode schizo-
phrenia sample,23 symptom improvements were
generally robust. There were high response and
remission rates, with accompanying improvements
in social and occupational functioning and quality
of life. Although caution is mandatory when com-
paring results across studies, outcomes from our
study compared favourably with those reported for
the European First-Episode Schizophrenia Trial
(EUFEST) in which several second-generation oral
antipsychotics and haloperidol were compared over
12 months of treatment. For example, for our study
versus EUFEST, respectively, all-cause discontinua-
tion rates were 28% versus 33–72%; response rates
(50% PANSS total score improvement, calculated
with the same correction as in the present study)
were 82% versus 37–67%; and remission rates 60%
versus 17–41%.24,25 Furthermore, although several of
our patients experienced relapses, few were treat-
ment refractory. The favourable outcomes in the
present study may be ascribable to the higher study
retention rates and assured adherence associated
with a long-acting injectable antipsychotic, as pre-
viously reported in a first-episode sample treated
with long-acting risperidone injection.26 However,
other factors could equally explain the observed dif-
ferences, including study design (open label, non-
comparative vs. randomized, comparative) and
cultural/ethnic differences in treatment response.
The low mean dose of flupenthixol decanoate that
patients received is consistent with previous reports
that first-episode patients require lower antipsy-
chotic doses27 and that low doses of first-generation
antipsychotics are just as effective as high doses in
first-episode patients.28
Tolerability
Although several patients experienced emergent
extrapyramidal symptoms and weight gain, the
treatment was generally well tolerated – particularly
when considering the exquisite sensitivity to
antipsychotics of first-episode patients29 and that
flupenthixol is a first-generation antipsychotic.
Indeed, the frequency and severity of extrapy-
ramidal symptoms – the most problematic side
effect of first-generation antipsychotics – was not
dissimilar to that reported with some second-
generation antipsychotics in longitudinal studies in
first-episode samples,24,26,30,31 and the mean weight
gain of 8.4 kg over 12 months was less than that
reported for olanzapine (13.9 kg), quetiapine
(10.5 kg) and amisulpride (9.7 kg), but greater than
haloperidol (7.3 kg) and ziprasidone (4.8 kg) in the
EUFEST study.24 The relatively favourable tolerabil-
ity of the treatment could be ascribed to both our
low-dosing strategy and the fact that flupenthixol
has been described as a ‘partially atypical’ antipsy-
chotic.32 The demonstration of favourable tolerabil-
ity is important, given that the high acquisition costs
of second-generation antipsychotics put them
beyond the reach of most patients in LMICs.33
Indeed, a recent Cochrane review of flupenthixol
recommended that this inexpensive drug may well
be worthy of careful investigation.34
Maximizing the advantage of depot
antipsychotics
Surprisingly, clinical studies have failed to
unequivocally demonstrate the superiority of depot
over oral antipsychotics. Systematic reviews report
few outcome advantages for depots versus oral
antipsychotics.35,36 Indeed, the most recent system-
atic review and meta-analysis of randomized con-
trolled trials of depot versus oral antipsychotics
in schizophrenia reported that pooled depots
did not reduce relapse rates compared with oral
antipsychotics.37 These reviews highlight several
methodological challenges and shortcomings of
previous studies such as small samples, short study
duration and, particularly, selection bias. Non-
adherent patients, although being the most likely to
benefit from depot antipsychotic treatment, are less
likely to consent to participate. However, there are
other reasons why depot antipsychotics may have
failed to demonstrate advantages. First, most
studies have been conducted in chronic, multi-
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episode samples. Response to treatment is better in
the first episode compared with subsequent epi-
sodes,38 and the first 2–5 years have been proposed
as a ‘critical period’ during which the illness at its
most aggressive and the risk for relapse, disease pro-
gression and suicide is greatest.39 Non-adherence is
very common during the early stages of treatment.40
Therefore, addressing adherence in early phase of
illness with a depot antipsychotic would be consist-
ent with contemporary public health principles of
early effective intervention and prevention of accru-
ingmorbidity. The risk of treatment discontinuation
seems to be particularly high in the period between
acute and maintenance treatment, often after dis-
charge from hospital.6 Therefore, initiating depot
treatment during the acute treatment phase may
help bridge the treatment gap over this crucial tran-
sitional phase. A second possible reason for the
failure of depot antipsychotics to demonstrate clear
advantages is that on their own they may not
improve adherence, as patients may still default on
treatment. Addition of an AMP exploits the trans-
parency of depot treatment and may be the critical
component to improving adherence. Third, doses of
conventional depot antipsychotics were frequently
excessive in the past and resultant side effects may
have contributed to the high dropout rates observed
in clinical trials. We have found that low doses of
conventional oral antipsychotics had equal efficacy
and superior tolerability to higher doses in first-
episode schizophrenia.28 The low-dosing strategy
comprised initiating antipsychotic treatment at the
lowest possible dose, treating initial agitation with a
benzodiazepine rather than increasing the antipsy-
chotic dose, and gradual upward titration of antip-
sychotic dose as necessary until optimal response
was obtained.41
Considerations when using depot
antipsychotics in early illness
Despite general recognition of the enormity of the
non-adherence problem in schizophrenia, depot
antipsychotics are only prescribed in a small pro-
portion of patients in clinical practice.42 Particularly,
their use in the early stages of illness has been
limited. Systematic reviews of depot antipsychotics
in first-episode and early schizophrenia report that
most studies to date were post-hoc analyses of
larger datasets and involved second-generation
long-acting injectable antipsychotics43,44 that are
beyond the reach of patients in LMICs. The use of
depot antipsychotic in first-episode schizophrenia
is controversial presumably due to concerns regard-
ing individual autonomy, coercion and dignity,43
and the preconceived view of some psychiatrists
that patients are unwilling to accept injections in
the early stages of illness.45 A counter-argument
would be that the best way to promote individual
autonomy and dignity is to achieve sustained remis-
sion bymeans of continuous treatment, and studies
have reported considerable patient preference for
depots, with those who receive depots being gener-
ally satisfied with this treatment.46 Indeed, patients
with a high level of insight, favourable attitude
towards drug treatment and good understanding of
the disease may choose depot rather than oral
antipsychotic treatment.47
The use of a depot antipsychotic in acute phase
illness and in first-episode patients may also raise
some safety concerns, given the increased sensitivity
of these individuals to antipsychotics and the fact
that depot antipsychotic blood levels persist for a
long time after discontinuation. Drug sensitivity
reactions are a concern, as are severe extrapyramidal
side effects including neuroleptic malignant syn-
drome. For this reason, it is obligatory to test for
hypersensitivity with oral medication before initiat-
ing depot treatment. Importantly, no increased risk
of extrapyramidal side effects including neuroleptic
malignant syndrome has been reported with depot
antipsychotics compared with their oral counter-
parts.35,48 Theremay also be a concern that introduc-
ing a depot as first-line treatment in the first episode
may result in some patients receiving unnecessary
long-term antipsychotic exposure. However, guide-
lines generally recommend treatment of a first
episode of schizophrenia for at least 12–24 months
for those who achieve symptom stabilization,49,50
and our own and others’ experience with first-
episode schizophrenia (including schizophreniform
disorder) was that the vast majority relapsed when
antipsychotic treatment was discontinued.51–53
Given the enormous risks associated with relapse
and the absenceof reliable relapsepredictors, longer
periods of treatment are increasingly advocated.5
Clinicians may however sometimes decide to dis-
continue antipsychotic treatment in a particular
patient, for example, due to uncertain or changed
diagnosis. In such a situation, as with oral
antipsychotics, depot antipsychoticsmaybediscon-
tinued at any stage of treatment. Finally, use of a
depot plus AMP could be construed as overempha-
sizing the pharmacological aspects of treating
schizophreniaandneglecting the importanceofpsy-
chosocial interventions. Psychosocial interventions
in conjunction with antipsychotic treatment are
effective in improving adherence and reducing
relapse rates,54 and as such should be part of the
comprehensive package of care provided to patients
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with schizophrenia. However, many of these inter-
ventions are time consuming and costly, and fre-
quently require the availability of health-care
workers with high levels of skills. Consequently,
many health-care settings around the world are not
able to provide these services. The AMP has several
important psychosocial components, including
psychoeducation, shared decision-making, and
establishing positive relationships with patients and
carers that enhance adherence and outcome.
Furthermore, the AMP does not preclude inclusion
in any other psychosocial interventions that may be
available to patients.
Limitations and future directions
Our findings are not necessarily generalizable to
other clinical settings where, for example, attitudes
to injections and access to services may differ.
However, the combination of low-dose conven-
tional antipsychotic depot with AMP may be an
effective and cost-effective way of managing early-
phase schizophrenia in settings beyond those in
LMICs. The major limitation of this study is that it
was non-comparative, and as such was not
designed to compare depot versus oral antipsy-
chotic treatment, or conventional versus second-
generation antipsychotics. Rather, it aimed to assess
the feasibility and effectiveness of using low-dose
first-generation depot antipsychotic plus AMP as
first-line acute and maintenance treatment in first-
episode schizophrenia. The logical next step would
be to conduct a pragmatic randomized controlled
trial comparing depot antipsychotic plus AMP with
depot without AMP andwith oral antipsychotic with
and without AMP in order to determine whether, as
we suspect, the addition of AMP is the critical factor.
A further study limitation is the possibility of sample
selection bias. It is possible that the patients who
agreed to participate in the study were those with a
better prognosis. We were unable to compare the
baseline characteristics of patients who agreed to
participate with those who declined, as we did not
collect baseline characteristics of participants who
declined participation.
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A B S T R A C T
Objectives: To assess changes in body mass and metabolic proﬁles in patients with ﬁrst-episode
schizophrenia receiving standardised, assured treatment and to identify predictors and moderators of
the effects.
Methods: We investigated the changes in body mass, fasting blood glucose and lipids in 107 largely
antipsychotic naı¨ve, ﬁrst-episode schizophrenia patients who were treated according to a standard
algorithm with long-acting injectable ﬂupenthixol decanoate over 12 months.
Results: Eighty-three (78%) participants completed the 12 months of treatment, and 104 (97%) received
100% of the prescribed injections during their participation. There were signiﬁcant increases in BMI
(P < .0001), waist circumference (P = 0.0006) and triglycerides (P = 0.03) and decrease in HDL (P = 0.005),
while systolic (P = 0.7) and diastolic blood pressure (P = 0.8), LDL (P = 0.1), cholesterol (P = 0.3), and
glucose (P = 0.9) values did not change over time. The triglyceride: HDL ratio increased by 91%. Change in
BMI was only correlated with change in triglycerides (P = .008). The only signiﬁcant predictor of BMI
increase was non-substance abuse (P = .002).
Conclusions: The risks of weight gain and metabolic syndrome associated with antipsychotic treatment in
ﬁrst-episode schizophrenia are not restricted to second generation antipsychotics. This is a global
problem, and developing communities may be particularly susceptible.
 2015 Published by Elsevier Masson SAS.
Contents lists available at ScienceDirect
European Psychiatry
jo u rn al h om epag e: h t tp : / /ww w.eu ro p s y- jo ur n al .co m1. Introduction
Patients with schizophrenia are at increased risk of weight gain,
metabolic syndrome (MetS), cardiovascular disease and mortality
[29]. While factors such as sedentary lifestyle [6], smoking and
poor diet play a role [41], it is now recognised that antipsychotics,
via their adipogenic and dysmetabolic effects, are major con-
tributors [10,15]. Young people experiencing a ﬁrst-episode of
psychosis with no or limited previous antipsychotic exposure are
most susceptible [4,9,17,35,48]. The risk of weight gain varies
amongst individuals and this may be genetically determined* Corresponding author. Department of Psychiatry, Faculty of Medicine and
Health Sciences, Stellenbosch University, Tygerberg 7505, Cape Town, South Africa
Tel.: +27 21 938 9227; fax: +27 21 938 9738.
E-mail address: bonga@sun.ac.za (B. Chiliza).
http://dx.doi.org/10.1016/j.eurpsy.2014.11.013
0924-9338/ 2015 Published by Elsevier Masson SAS.[27]. Also, the risk varies between individual antipsychotics. While
most attention has focused on second-generation antipsychotics
(SGAs), low potency ﬁrst-generation antipsychotics (FGAs) are
reported to carry a similar risk [26]. Other FGAs have not been
associated with weight gain and, apart from haloperidol, have not
generally been studied–despite the fact that they continue to be
extensively used, particularly in lower-income countries. Con-
siderable attempts have been made to identify clinical and
laboratory predictors of weight gain. Predicting patients at risk
for weight gain would be beneﬁcial as interventions could then be
tailored speciﬁcally to those patients who are at highest risk of
weight gain. Previously identiﬁed predictors of weight gain have
included sex, age, ethnicity and low BMI [48], however there have
been conﬂicting results. Advances in pharmacogenomics have
yielded the most promising results in predicting severe weight
gain in some individuals [8].
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metabolic proﬁles are confounded by many factors, thereby
making it impossible to draw ﬁrm conclusions from much of
the published literature [18]. Many studies are limited by factors
such as small sample sizes, brief evaluation periods, poorly
characterised patient samples, non-standardisation of treatment
and failure to assess the effects of dosage and non-adherence.
Furthermore, interpretation of study results is often complicated
by the use of inappropriate statistical analyses. For example, last-
observation carried forward (LOCF) analyses are likely to under-
estimate drug effects [18,21,48], as longitudinal studies frequently
have high rates of discontinuation. Similarly, observed cases, or per
protocol samples may be biased as reasons for study discontinua-
tion may not be random. Non-adherence is also likely to be a major
cause of underreporting of effects of antipsychotics on body mass
and metabolic proﬁles, with most studies either not assessing
adherence, or utilising methods with inherent inaccuracies
[46]. Non-adherence may be particularly relevant in early
psychosis, given the very high rates reported in early phases of
treatment of schizophrenia [18,45]. Finally, notwithstanding the
fact that comorbid substance abuse is very common in schizo-
phrenia, many studies either excluded these patients from their
samples, or failed to assess their effects on body mass and
metabolic changes. The above limitations have been highlighted
and additional recommendations made, including the testing for
dosage effects, controlling for age and sex and adoption of
Consolidated Standards of Reporting Trials (CONSORT) [38] or
Strengthening the Reporting of Observational Studies in Epide-
miology (STROBE) [47] guidelines to increase accuracy of reporting
and of interpreting [18].
We conducted a study that was able to address several of these
potential confounders. We selected ﬁrst-episode, largely treat-
ment-naı¨ve patients and conducted regular, standardised assess-
ments of body mass and metabolic proﬁle during the course of
treatment according to a standard protocol, with a single long-
acting injectable antipsychotic which provided assured medication
adherence. Also, we excluded comorbid medical conditions and
carefully assessed the role of substance abuse. Studies to date have
involved predominantly Caucasian and Chinese patient samples
[44]. As far as we are aware, this is the ﬁrst longitudinal study
assessing weight-gain and its metabolic concomitants in an African
sample, and the cohort, comprising largely individuals of mixed
ancestry from the greater Cape Town region, may represent an
economically emerging, particularly at-risk community for meta-
bolic syndrome [14]. Finally, to the best of our knowledge this is
the ﬁrst study prospectively assessing the effects of ﬂupenthixol on
body mass and metabolic proﬁles.
Our study aimed to assess changes in body mass and metabolic
proﬁles in patients with ﬁrst-episode schizophrenia receiving
standardised, assured treatment over 12 months, and to identify
predictors and moderators of these effects. We hypothesised that
there would be substantial weight gain which would be
signiﬁcantly correlated with changes in lipid and glucose proﬁles,
and emergent cases of MetS.
2. Methods
This was a single-site cohort study. Approval was obtained from
the Human Research Ethics Committee of Stellenbosch University
Faculty of Medicine and Health Sciences. The study was conducted
in accordance with the International Conference on Harmonization
guidelines on good clinical practice (GCP) [23] and was registered
at the South African National Clinical Trials Register (DOH-27-
0710-1957), URL: www.sanctr.gov.za/SAClinicalTrials/tabid/169/
Default.aspx.3. Participants
Subjects were recruited from ﬁrst-admissions to psychiatric
hospitals and community clinics within our catchment areas in
Cape Town between April 2007 and March 2011. Patients and/or
their legal guardians provided written, informed consent. Eligible
participants were men and women, in- or outpatients, aged 16 to
45 years, meeting Diagnostic and Statistical Manual of Mental
Diseases, Fourth Edition (DSM-IV) [5] diagnostic criteria for
schizophreniform disorder, schizophrenia or schizo-affective dis-
order. Patients were excluded if they had, during their lifetime, been
exposed to > 4 weeks of antipsychotic medication, been treated
with a long-acting depot antipsychotic, had a serious or unstable
medical condition, mental retardation or overt substance abuse.
4. Assessments
A physical examination was conducted at the start and
completion of the study. For anthropometric measurements
patients removed all surplus clothing including shoes and socks
and were weighed on a regularly calibrated electronic scale. Waist
circumference (WC) was measured between the lowest rib and the
iliac crest with patients standing upright and breathing normally.
Body mass index (BMI) was calculated as the weight in kilograms
divided by the square of height in meters. Weight was assessed at
baseline, week 6, and months 3, 6, 9 and 12. Laboratory tests were
conducted at baseline, 3, 6 and 12 months. Laboratory tests
comprised fasting glucose, high density lipoprotein cholesterol
(HDL), low density lipoprotein cholesterol (LDL), triglycerides and
total cholesterol, as well as urine toxicology for cannabis,
methaphetamines and methaqualone. For these tests patients
fasted for at least 8 hours overnight and rested for 10 min prior to
venipuncture. We used the Adult Treatment Panel (ATP III-A)
criteria proposed by the American Heart Association for MetS
[2]. MetS criteria comprise raised blood pressure, raised triglycer-
ides, lowered high-density lipoprotein cholesterol, raised fasting
blood glucose, and central obesity according to WC. Cut-off values
for WC ( 90 cm men,  80 cm women) were adapted to our
speciﬁc population norms [28]. Abnormal values for any 3 of the
5 criteria would qualify an individual for MetS.
Patients were assessed with the Structured Clinical Interview
for DSM-IV (SCID) [16] and psychopathology was assessed by the
Positive and Negative Syndrome Scale (PANSS) [24] and the
Calgary Depression Scale for Schizophrenia (CDSS) [1]. Clinical
outcomes will be reported separately.
5. Treatment
There was a one week lead-in period of oral ﬂupenthixol 1 to
3 mg/day followed by long acting ﬂupenthixol decanoate injec-
tions every two weeks for the duration of the study. The initiation
dose was 10 mg 2-weekly. Additional oral ﬂupenthixol was
prescribed at the discretion of the investigator. Permitted
concomitant treatment included medication for general medical
conditions, lorazepam for sedation, orphenadrine or biperiden for
extrapyramidal symptoms and propranolol for akathisia. No
benzodiazepines, propranolol or anticholinergics were permitted
in the 12 hours prior to assessments. Medications not permitted
included other antipsychotics, mood stabilizers and psychostimu-
lants.
6. Statistical methods
Analyses were performed on a modiﬁed intent-to-treat basis,
meaning that all patients were included in the analysis if they had a
Fig. 1. Study proﬁle diagram.
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Kolmogorov-Smirnov test for weight, waist circumference, systolic
and diastolic blood pressure and none of the variables had a P-
value of < 0.05. We employed linear mixed effect models for
continuous repeated measures (MMRM) to assess the changes in
BMI and metabolic indices over time. Visit-wise changes were
assessed using a model that included ﬁxed terms of age, gender,
baseline measure, substance abuse and endpoint ﬂupenthixol
dose. Due to some deviations from normal distribution, we also
performed the analyses on log transformed data. These results are
not reported as they did not differ from the non-transformed
results. We conducted Pearson correlational coefﬁcient analyses to
explore associations between changes in BMI and metabolic
indices. Change scores were calculated by subtracting the baseline
score from the endpoint (LOCF) score. We conducted a predictor
analysis to identify demographic and baseline variables that best
predicted change in BMI. The variables we considered were age,
gender, ethnicity, duration of untreated psychosis (DUP), baseline
scores for PANSS positive subscale, PANSS negative subscale,
PANSS general subscale, CDSS, BMI, fasting glucose, HDL, LDL,
triglycerides and cholesterol. As there was an indication of
multicollinearity, we conducted best subsets regression analysis.
To assess the effect of antipsychotic dose on body mass, we
calculated least squares means for BMI according to the endpoint
dose of ﬂupenthixol decanoate. All tests were 2-tailed and a
signiﬁcance level of .05 was used throughout. None of the analyses
were corrected for multiple comparisons. Descriptive statistics are
reported as the mean (SD) at baseline, at 12 months (per protocol)
and endpoint (LOCF).
7. Results
The study proﬁle diagram is provided as Fig. 1. The sample
analysed (n = 107) comprised 77 (72%) men and 30 (28%) women
with a mean age of 24 (SD 6.5) years. Race distribution was as
follows: mixed ancestry (n = 82, 77%), black (n = 15, 14%) and white
(n = 10, 9%). The South African mixed ancestry population, or so-
called South African Coloured population, is a unique population
with a complex genetic history that is largely made up of Khoisan
genes admixed with African, European and a smaller Asian
contribution [11]. Patients who self-identiﬁed as South African
Coloured were included under mixed ancestry category. DSM IV
diagnoses were schizophrenia (n = 61, 59%), schizophreniform
disorder (n = 43, 40%) and schizo-affective disorder (n = 1, 1%).
Mean DUP was 34 (SD 43.2) weeks and the mean baseline PANSS
total score was 95 (SD 16.1). Fifty (47%) patients had a history of
substance abuse and 48 (45%) had previous exposure toTable 1
Mean (SD) baseline, 12-month (per protocol) and endpoint (LOCF) values for anthropo
Baseline (n = 107) 12 month
Mean Std. Dev. Mean 
BMI (kg/m2) 21.6 3.9 24.5 
Weight (kg) 61 12 69 
WC (cm) 77 11 84 
Systolic BP (mmHg) 121 14 123 
Diastolic BP (mmHg) 80 10 80 
Glucose (mmol/L) 4.8 0.7 5.0 
HDL (mmol/L) 1.2 0.6 1.0 
LDL (mmol/L) 2.7 0.9 2.8 
Triglycerides (mmol/L) 0.9 0.5 1.2 
Cholesterol (mmol/L) 4.2 1.1 4.3 
Tryglyceride/HDL 0.9 0.7 1.3 
WC = waist circumference; BP = blood pressure; HDL = high density lipoprotein choleste
* Linear mixed effect models for continuous repeated measures (MMRM).
** t-test baseline vs. endpoint.antipsychotics, for a mean duration of 11 (SD 6.8) days. Our
window period for the 2-weekly injections was 3 days. While
patients sometimes went beyond this period, treatment adher-
ence, calculated as the number of actual injections received
divided by the prescribed number of injections, was 100% for 104
(97%) patients, and 60%, 56% and 55% for one patient each.
Details of the results for physical and laboratory assessments at
baseline, 12 months and endpoint are provided in Table 1. There
were statistically signiﬁcant increases in BMI, weight, WC and
triglycerides and signiﬁcant decrease in HDL, while systolic and
diastolic blood pressure, LDL, cholesterol and glucose values did
not change signiﬁcantly over time. The number of patients with
individual MetS risk factors, as well as those meeting full MetS
criteria [2] at baseline, month 12 and endpoint, are provided inmetric, blood pressure and metabolic measures.
s (n = 83) Endpoint (n = 107) P
Std. Dev. Mean Std. Dev.
5.1 24.3 4.9 < .0001*
14 68 14 < .0001**
12 83 12 0.0006**
13 122 14 0.7**
10 79 11 0.8**
1.5 5.0 1.4 0.9*
0.3 1.0 0.3 0.005*
0.8 2.8 0.9 0.1*
0.8 1.2 0.9 0.03*
0.9 4.3 0.9 0.3*
1.0 1.4 1.2 0.003*
rol; LDL = low density lipoprotein cholesterol.
Table 2
Number (%) of patients with individual MetS criteria, and those meeting full MetS criteria (3/5 criteria) at baseline, month 12 (per protocol) and endpoint (LOCF).
Baseline (n = 107) Month 12 (n = 83) Endpoint (n = 107)
Elevated WC (> 90 cm men, > 80 cm women) 13 (12%) 26 (31%) 29 (27%)
Elevated triglycerides (> 1.7 mmol/L) 6 (6%) 11 (13%) 15 (14%)
Low HDL (< 1 mmol/L men, < 1.3 mmol/L women) 62 (58%) 53 (64%) 71 (66%)
Elevated systolic BP (> 130 mmHg) 28 (26%) 27 (33%) 33 (31%)
Elevated diastolic BP (> 85 mmHg) 38 (36%) 29 (35%) 37 (35%)
Elevated fasting glucose (> 5.5 mmol/L) 6 (6%) 7 (8%) 9 (8%)
At least 1 MetS criterion 86 (80%) 73 (88%) 94 (88%)
MetS full criteria (any 3/5 risk factors) 17 (16%) 21 (25%) 26 (24%)
WC = waist circumference; HDL = high density lipoprotein cholesterol; BP = blood pressure; MetS = metabolic syndrome.
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the 12 month treatment period. The increase in BMI was highly
signiﬁcant. There were no signiﬁcant effects for age (P = .8), sex
(P = .6), history of substance abuse (P = .2) or endpoint ﬂupenthixol
dose (P = .1). There were no signiﬁcant differences between the
ethnic groups regarding BMI (P = 0.4) and the metabolic para-
meters (P = 0.2 to 0.9). We repeated the analysis on the subset of
patients who had never been exposed to previous antipsychotic
treatment (n = 59; 55%) and the results were similar
(F[5,214] = 14.344, P < .0001). Twenty-three participants were
prescribed antidepressants at some point in the study. To assess
whether this could have had an effect on our results, we compared
them with the rest of the sample regarding changes in BMI and
metabolic indices from baseline to endpoint. No evidence for an
effect was found insofar as there were no signiﬁcant differences for
changes in BMI (P = 0.3), fasting glucose (P = 0.9), HDL (P = 0.3), LDL
(P = 0.7), triglycerides (P = 0.8) and total cholesterol (P = 0.6).
For the correlational analyses for changes from baseline to
endpoint, change in BMI was signiﬁcantly correlated with change
in WC (r = .8, P < .0001) and triglycerides (r = .34, P = .008), but not
with change in glucose (r = .1, P = .3), HDL (r = –.1, P = .3), LDL
(r = .2, P = .1) or total cholesterol (r = .2, P = .1). To better examine
the relationships between change in BMI and changes in the
metabolic measures over time we conducted MMRM analyses fo,r
the percentage change values over 12 months for these variables
(Fig. 3). The greatest magnitudes of change were observed in
triglyceride increases and HDL reductions, and this is reﬂected in a
91% increase in the triglyceride/HDL ratio. For the prediction
analysis, the only signiﬁcant predictor of BMI increase was absence
of history of substance abuse (P = .002). A model incorporating age,time; LS Means
Current effect: F(5, 434)=33.055, p=0.0000
(Computed for covariates at their means)
Vertical bars denote 0.95 confidence intervals
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Fig. 2. Least squares mean BMI over 12 months.sex, previous antipsychotic treatment, substance abuse, baseline
BMI, baseline fasting glucose, triglycerides, total cholesterol, HDL
and LDL provided an R2 = .22. The relationships between the
endpoint dose of ﬂupenthixol decanoate and least squares means
for BMI are provided in Fig. 4.
8. Discussion
Our cohort of ﬁrst-episode schizophrenia patients gained
considerable weight over their ﬁrst 12 months of antipsychotic
treatment. The mean baseline BMI of our sample of 21.6 (SD 3.9) is
somewhat lower than the adult population norm for South
Africans of 28.5 [39], which is consistent with their relatively
young age. The baseline BMI of our sample is very similar to that of
a ﬁrst-episode schizophrenia sample from Europe [25]. The
increase in body mass was already substantial at 6 weeks, and
continued throughout the study period. These results are
consistent with previous studies showing extensive weight gain
in ﬁrst-episode samples [4,8,42,44,47] and emphasise the exqui-
site sensitivity of these individuals to the adipogenic effects of
antipsychotics. While most attention has focussed on the weight
gain risk associated with SGAs and to a lesser extent low-potency
FGAs [26], our study shows that, in ﬁrst-episode patients, a similar
risk exists even when treated with an FGA that is not generally
associated with weight gain and has been reported not to cause
weight gain in patients with chronic schizophrenia [30].
We were able to make several important observations from our
study. First, we could assess the true weight-gain effects of an
antipsychotic when adherence was assured. Non-adherence is one
of the major potential confounders in longitudinal studies of
weight gain, and this may be particularly the case in the ﬁrst year oftime*measurement; LS Means
Current effect: F(12, 1070)=5.4109, p=.00000
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[45]. Second, another difﬁculty in determining the longer term
weight-gain effects of antipsychotics is the role of reduced drug
exposure and missing values due to high discontinuation rates
frequently associated with longitudinal studies [18]. Our relatively
high study retention rate (78%) allowed us to better assess the
long-term effects of an antipsychotic on weight-gain. Also, by
conducting MMRM as well as reporting per-protocol and endpoint
results, we were able to assess the impact of missing values.
Perhaps surprisingly, although endpoint BMI values were lower
than the per protocol and MMRM results the differences were not
marked, suggesting that, at least in our sample, early discontinua-
tion did not have a major impact on overall results. Finally, we
were able to demonstrate that the weight-gain effect was
unrelated to antipsychotic dose. The ﬁnding that fully adherent
patients may not be at much greater risk of weight gain than those
who are partially non-adherent is perhaps not surprising as the
vast majority of our patients (97%) were fully adherent to
treatment. Together these ﬁndings suggest that weight-gain is
unlikely to be a useful marker of antipsychotic adherence and that
dose-reduction may not be an effective strategy in dealing with
weight gain.
It is not known whether changes in lipid proﬁles or blood
glucose levels in the ﬁrst-episode of psychosis are independent of
weight changes [18]. We were able to address the temporal
relationships between these variables in our study. Together with
the increase in BMI we observed some signiﬁcant changes in the
lipid proﬁles of our patients. Particularly, the increases in TG and
reductions in HDL were signiﬁcant and together they gave rise to
an alarming increase in the TG/HDL ratio. This is of concern given
that the TG/HDL ratio is an atherogenic marker [13,19] and a
powerful independent predictor of all-cause mortality and
cardiovascular events [34]. Our ﬁndings of greatly elevated TG/
HDL ratio are therefore consistent with, and provide a rational
basis for the ﬁnding that the most common cause of death in
schizophrenia is cardiovascular disease [34]. The fact that the
weight and metabolic changes occurred in patients treated with an
FGA is consistent with work that suggests that, while individual
antipsychotics differ in their effects on body weight, lipids and
glucose regulation in chronic schizophrenia, ﬁrst-episode patients
may be susceptible to these effects with a wider range of
antipsychotics [9,48]. Indeed, a recent systematic review found
no evidence of signiﬁcant differences between FGAs and SGAs in
terms of weight gain after 1 year [18], and it has been reported thatcardiometabolic outcomes were not different across different
antipsychotic treatments [36]. Another notable ﬁnding in the
present study was the increase in numbers of patients with
individual MetS risk factors as well as those meeting full MetS
criteria. The baseline MetS rate of 16% in our sample is
considerably higher than that reported in unmedicated (9.8%)
and ﬁrst-episode (9.9%) patients in a meta-analysis using similar
MetS criteria to ours [32]. This may reﬂect the particular risk of
MetS even in young individuals in emerging economies globally
[22]. Our cohort comprised largely individuals of mixed ethnicity
in the greater Cape Town area – a community where the
prevalence of MetS and diabetes has hugely increased in recent
years and is predicted to reach epidemic proportions [14]. We did
not ﬁnd any ethnic differences on weight and other metabolic
parameters in our cohort; however other studies have found that
African patients are at higher risk of antipsychotic induced weight
gain [43]. After 12 months of treatment the prevalence of MetS in
our cohort had increased to 25% and the percentage of patients
with at least one MetS risk factor had increased from 80% at
baseline to 88% after 12 months. The most frequently occurring
risk factors in our sample were low HDL and elevated blood-
pressure. Unexpectedly, we did not observe a signiﬁcant elevation
in fasting blood glucose levels during the 12-month treatment
period, suggesting that glycaemic dysregulation is a later
complication of antipsychotic treatment. This ﬁnding is in contrast
to a study reporting substantial worsening of fasting blood glucose
levels over 52 weeks of treatment with several SGAs and
haloperidol in European ﬁrst-episode patients [17], but is
consistent with a reported lack of correlation between weight
gain and blood glucose levels with both olanzapine and haloperidol
treatment in ﬁrst-episode patients treated over 12 months
[18,48]. Our failure to identify signiﬁcant correlations between
BMI change and metabolic changes other than triglycerides
supports the proposal that different mechanisms may be involved
and at least some metabolic effects of antipsychotics are weight-
independent [31].
Not all patients are at equal risk of weight gain with
antipsychotics and reliable markers for those at risk would be
hugely beneﬁcial. The fact that we were only able to identify one
signiﬁcant predictor highlights the difﬁculty in identifying reliable
clinical and laboratory predictors of weight gain with antipsycho-
tic treatment [48]. Female sex has been reported as a risk factor for
weight gain with antipsychotic treatment [20]. However, we and
others [9,48] did not ﬁnd such an association, and our results
suggest that sex effects may be confounded by substance abuse,
given that the only signiﬁcant predictor of BMI increase that we
identiﬁed was non-substance abuse. Substance abuse is more
common in men than in women in patients with ﬁrst-episode
schizophrenia [33]. Also, an inverse relationship has been reported
between baseline BMI and the magnitude of subsequent weight
gain during antipsychotic treatment [37]. However, it has been
proposed that this may be a spurious ﬁnding and could be
explained by a statistical artefact, namely regression to the mean
[3]. The small degree of variability explained by our predictor
model (22%) highlights our inability to accurately identify which
individuals are at risk of weight gain [26,48] and suggests that
factors other than those included in our model should be examined
for their predictive power. In future, pharmacogenetic strategies
may be especially useful, and new developments in genomics are
providing informative data on the genes associated with psycho-
tropic drug weight gain [8]. For example, it has been reported that a
subset of approximately one quarter of patients experience severe
weight gain when treated with SGAs, and that this risk may be
genetically conferred, with common variants at a locus near the
melanocortin 4 receptor gene being speciﬁcally implicated [27]. In
that study, severe weight gain was deﬁned as > 14% gain from
B. Chiliza et al. / European Psychiatry 30 (2015) 277–283282
55
Stellenbosch University  https://scholar.sun.ac.zabaseline after 12 weeks of treatment. It is of interest that, when we
applied the same criteria to our own sample we found a similar
result – 23% of our patients met these criteria for severe weight
gain at 12 weeks.
Flupenthixol, ﬁrst introduced almost 50 years ago, is widely
available and remains a popular choice by psychiatrists in both
high and low income settings for treating people with psychosis.
Flupenthixol, belonging to the thioxanthene class, is a high potency
FGA. However, its receptor binding proﬁle is not dissimilar to
several SGAs, as it antagonises D1-5 dopamine, 5-HT2, H1 histamine
and alpha1 adrenergic receptors [12]. Its use is based on anecdotal
experience rather than well-conducted clinical studies and little is
known about its tolerability and efﬁcacy proﬁle. According to a
recent Cochrane review there are few data from clinical trials
investigating its absolute effects, and the authors concluded that
ﬂupenthixol may well be worthy of careful investigation, partly to
ensure that this inexpensive active drug is not forgotten [40].
Strengths of the study include the fact that this was a largely
unmedicated ﬁrst-episode sample, thereby circumventing possible
effects of disease chronicity and previous antipsychotic exposure.
Also, by following a standard treatment protocol with a single
antipsychotic, we avoided the confounding differential weight-
gain effects of different antipsychotics. Finally, using a long-acting
injectable antipsychotic addressed the problem of partial and non-
adherence, and the consequent high rates of study retention
enhanced our ability to assess true long-term weight-gain and
metabolic effects by reducing the numbers of missing variables.
Limitations include the absence of a healthy control group
which meant that we were unable to assess the changes in weight
and metabolic proﬁle over time in young people in the community
from which our patients were recruited. We did not measure
fasting insulin levels which could have informed us about insulin
resistance which is usually a precursor to increased fasting glucose.
Also, we did not assess the effects of smoking, diet or the levels of
activity in our patients. Finally, our ﬁndings may not be
generalisable to antipsychotics other than ﬂupenthixol, and also
to populations other than the one studied here. Nevertheless,
results from this carefully selected, treated and assessed cohort
provide several insights into effects of an antipsychotic on weight
and metabolic proﬁles. The results highlight the magnitude of the
problem, that the risk is not restricted to those patients treated
with SGAs or low-potency FGAs and that this represents a global
health challenge, affecting both high and low income commu-
nities.
Disclosure of interest
L.A., Y.vN., R.E., M.K. and A.M. declare that they have no conﬂicts
of interest concerning this article. B.C. has received honoraria from
Sandoz and Janssen for speaking at educational meetings. P.O. has
received honoraria from Pﬁzer, Lundbeck, Astra-Zeneca and Cipla
for speaking at educational meetings. R.A.E has received honoraria
from AstraZeneca, Bristol-Myers Squibb, Janssen, Lilly, Lundbeck,
Organon, Pﬁzer, Servier, Otsuka and Wyeth for participating in
advisory boards and speaking at educational meetings, and has
received research funding from Janssen, Lundbeck and AstraZe-
neca.
Acknowledgement
Study medication was kindly provided by Lundbeck, South
Africa.
Funding: This study was made possible by a New Partnership for
Africa’s Development (NEPAD) grant, through the Department of
Science and Technology of South Africa, the Medical ResearchCouncil of South Africa and an unrestricted grant from Lundbeck
International.
References
[1] Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizo-
phrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993;22(22):
39–44.
[2] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.
Harmonizing the metabolic syndrome: a joint interim statement of the
International Diabetes Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation 2009;120(16):1640–5.
[3] Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the
relationship between baseline BMI and subsequent weight change in antipsy-
chotic trials: effect modiﬁcation or regression to the mean? Psychiatry Res
2009;170(2–3):172–6.
[4] Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, Hetrick S, Rodri-
guez-Sanchez JM, Perez-Iglesias R, et al. Antipsychotic-induced weight gain in
chronic and ﬁrst-episode psychotic disorders: a systematic critical reappraisal.
CNS Drugs 2008;22(7):547–62.
[5] American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders IV-TR. Washington, DC: American Psychiatric Association; 2000.
[6] Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with
schizophrenia. Psychol Med 1999;29(3):697–701.
[7] Coldham EL, Addington J, Addington D. Medication adherence of individuals
with a ﬁrst episode of psychosis. Acta Psychiatr Scand 2002;106(4):286–90.
[8] Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol
Med 2011;17(2):97–107.
[9] Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.
Cardiometabolic risk of second-generation antipsychotic medications during
ﬁrst-time use in children and adolescents. JAMA 2009;302(16):1765–73.
[10] De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular
disease and diabetes in people with severe mental illness position statement
from the European Psychiatric Association (EPA), supported by the European
Association for the Study of Diabetes (EASD) and the European Society of
Cardiology (ESC). Eur Psychiatry 2009;24(6):412–24.
[11] de Wit E, Delport W, Rugamika CE, Meintjes A, Mo¨ller M, van Helden PD, et al.
Genome-wide analysis of the structure of the South African Coloured Popula-
tion in the Western Cape. Hum Genet 2010;128:145–53.
[12] de Wit H. Flupenthixol. In: Stolerman IP, editor. Encyclopedia of psychophar-
macology:. Springer; 2010.
[13] Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an athero-
genic index: correlation with lipoprotein particle size and esteriﬁcation rate in
apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001;34(7):
583–8.
[14] Erasmus RT, Soita DJ, Hassan MS, Blanco-Blanco E, Vergotine Z, Kegne AP, et al.
High prevalence of diabetes mellitus and metabolic syndrome in a South
African coloured population: baseline data of a study in Bellville, Cape Town. S
Afr Med J 2012;102(11 Pt 1):841–4.
[15] Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. The
METEOR study: frequency of metabolic disorders in patients with schizophre-
nia. Focus on ﬁrst and second generation and level of risk of antipsychotic
drugs. Int Clin Psychopharmacol 2011;26(6):291–302.
[16] First MB. Structured clinical interview for DSM-IV axis I disorders, SCID-I:
clinician version. Washington, D.C: American Psychiatric Press; 1997.
[17] Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS,
et al. Metabolic risk factors in ﬁrst-episode schizophrenia: baseline prevalence
and course analysed from the European First-Episode Schizophrenia Trial. Int J
Neuropsychopharmacol 2013;16(5):987–95.
[18] Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of
the ﬁrst treated episode of psychosis. Arch Gen Psychiatry 2011;68(6):609–16.
[19] Frohlich J, Dobiasova M. Fractional esteriﬁcation rate of cholesterol and ratio of
triglycerides to HDL-cholesterol are powerful predictors of positive ﬁndings
on coronary angiography. Clin Chem 2003;49(11):1873–80.
[20] Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N,
Remschmidt H, Krieg JC, et al. Antipsychotic-induced body weight gain:
predictors and a systematic categorization of the long-term weight course.
J Psychiatr Res 2009;43(6):620–6.
[21] Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington
G, et al. Recent advances in understanding and mitigating adipogenic and
metabolic effects of antipsychotic drugs. Front Psychiatry 2012;28(3):62.
[22] Gupta N, Shah P, Nayyar S, Misra A. Childhood obesity and the metabolic
syndrome in developing countries. Indian J Pediatr 2013;80(Suppl. 1):S28–37.
[23] International Conference on Harmonization. ICH Harmoniesed Tripartite
Guidelines for Good Clinical Practice. Surrey: Brookwood Medical Publications
Ltd; 1996.
[24] Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS)
for schizophrenia. Schizophr Bull 1987;13(2):261–76.
[25] Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al.
Effectiveness of antipsychotic drugs in ﬁrst-episode schizophrenia and
schizophreniform disorder: an open randomised clinical trial. Lancet
2008;371(9618):1085–97.
B. Chiliza et al. / European Psychiatry 30 (2015) 277–283 283
56
Stellenbosch University  https://scholar.sun.ac.za[26] Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus
ﬁrst-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lan-
cet 2009;373(9657):31–41.
[27] Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, et al.
Association between common variants near the melanocortin 4 receptor gene
and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry
2012;69(9):904–12.
[28] Matsha TE, Hassan MS, Hon GM, Soita DJ, Kengne AP, Erasmus RT. Derivation
and validation of a waist circumference optimal cutoff for diagnosing meta-
bolic syndrome in a South African mixed ancestry population. Int J Cardiol
2013;168(3):2954–5.
[29] McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al.
Prevalence of the metabolic syndrome in patients with schizophrenia: base-
line results from the Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) schizophrenia trial and comparison with national estimates from
NHANES III. Schizophr Res 2005;80(1):19–32.
[30] Messer T, Glaser T, Landen H, Schmauss M. Long-term treatment with ﬂu-
pentixol results of a post-marketing surveillance study. J Psychopharmacol
2009;23(7):805–13.
[31] Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline
concordant monitoring of metabolic risk in people treated with antipsychotic
medication: systematic review and meta-analysis of screening practices.
Psychol Med 2012;42(1):125–47.
[32] Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of
metabolic syndrome and metabolic abnormalities increased in early schizo-
phrenia? A comparative meta-analysis of ﬁrst episode, untreated and treated
patients. Schizophr Bull 2013;39(2):295–305.
[33] Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophre-
nia and ﬁrst-episode psychosis: a comprehensive literature review. Schizophr
Res Treat 2012;2012:916198.
[34] Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death
in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45(1–
2):21–8.
[35] Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al.
Metabolic proﬁles of second-generation antipsychotics in early psychosis:
ﬁndings from the CAFE study. Schizophr Res 2009;111(1–3):9–16.
[36] Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry
2010;23(6):574–81.[37] Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al.
Weight gain associated with olanzapine and risperidone in adolescent
patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry
2002;41(3):337–43.
[38] Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement:
updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med
2010;7(3):e1000251. http://dx.doi.org/10.1371/journal.pmed.1000251.
[39] Shisana O, Labadarios D, Rehle T, Simbayi L, Zuma K, Dhansay A, et al. South
African National Health and Nutrition Examination Survey (SANHANES-1).
Cape Town: HSRC Press; 2014.
[40] Shen X, Xia J, Adams CE. Flupenthixol versus placebo for schizophrenia.
Cochrane Database Syst Rev 2012;11:CD009777.
[41] Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with
schizophrenia: a preliminary study. Schizophr Bull 2003;29(2):393–7.
[42] Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diag-
nosed ﬁrst-episode psychosis patients and healthy comparisons: one-year
analysis. Schizophr Res 2007;93(1–3):90–8.
[43] Stauffer VL, Sniadecki JL, Piezer KW, Gatz J, Kollack-Walker S, Hoffmann VP,
Conley R, Durell T. Impact of race on efﬁcacy and safety during treatment with
olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
BMC Psychiatry 2010;10:89. http://dx.doi.org/10.1186/1471-244X-10-89.
[44] Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in
antipsychotic-naive patients: a review and meta-analysis. Psychol Med
2010;40(2):187–200.
[45] Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nation-
wide cohort study of oral and depot antipsychotics after ﬁrst hospitalization
for schizophrenia. Am J Psychiatry 2011;168(6):603–9.
[46] Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. Assess-
ment of adherence problems in patients with serious and persistent mental
illness: recommendations from the Expert Consensus Guidelines. J Psychiatr
Pract 2010;16(1):34–45.
[47] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
STROBE Initiative. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting observational
studies. Lancet 2007;370(9596):1453–7.
[48] Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course
and predictors of weight gain in people with ﬁrst-episode psychosis treated
with olanzapine or haloperidol. Br J Psychiatry 2005;187:537–43.
 
 
 
 
 
 
 
Chapter 5 
Rate and predictors of non-response to first-line antipsychotic 
treatment in first-episode schizophrenia 
  
57
Stellenbosch University  https://scholar.sun.ac.za
Rate and predictors of non-response to ﬁrst-line antipsychotic
treatment in ﬁrst-episode schizophrenia†
Bonginkosi Chiliza *, Laila Asmal , Sanja Kilian , Lebogang Phahladira and Robin Emsley
Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
Objective The goals of this study were to (i) estimate the rate of non-response to ﬁrst-line treatment in ﬁrst-episode schizophrenia, (ii) eval-
uate other outcomes associated with symptom non-response and (iii) identify demographic, baseline clinical and early treatment response pre-
dictors of non-response.
Methods This was a single-site, longitudinal cohort study assessing the effects of treatment with ﬂupenthixol decanoate according to a
standardised protocol over 12months in patients with schizophrenia, schizophreniform and schizo-affective disorders.
Results Of 126 patients who received at least one dose of study medication, 84 (67%) completed the study. Fifteen (12%) met our
predeﬁned criteria for non-response. Non-responders were younger and at baseline had more prominent disorganised symptoms, poorer so-
cial and occupational functioning, poorer quality of life for psychological, social and environmental domains, more prominent neurological
soft signs (NSS) and lower body mass index. At endpoint, the non-responders were characterised by higher levels of symptomatology in all
domains, poorer functional outcome, poorer quality of life and greater cognitive impairments. They also had more prominent NSS and lower
body mass index. The strongest predictors of non-response were more prominent baseline NSS and poor early (7weeks) treatment response.
Conclusions Results are consistent with a lower rate of refractoriness to treatment in ﬁrst-episode schizophrenia compared with multi-
episode samples. Copyright © 2015 John Wiley & Sons, Ltd.
key words—non-response; ﬁrst-episode psychosis; predictors; outcome; neurological soft signs
INTRODUCTION
Treatment outcome has been extensively studied in
ﬁrst-episode schizophrenia. However, the majority of
studies have primarily focused on favourable outcome
measures such as response, remission and recovery.
Others have investigated relapse in patients who have
responded to treatment. Few studies have investigated
non-response from the outset as the primary outcome
in ﬁrst-episode samples (Menezes et al., 2006), not-
withstanding the fact that there are good reasons to do
so. Persistence of psychotic symptoms causes ongoing
distress, diminished autonomy, poor quality of life
and increased morbidity and mortality for affected indi-
viduals. It also places emotional and ﬁnancial burdens
on carers and excessive demands on healthcare services
(Van Sant and Buckley, 2011; Kennedy et al., 2014).
The importance of early, effective treatment in optimising
the long-term outcome of the illness is well recognised
(Amminger et al., 2011). The early identiﬁcation of indi-
viduals failing to respond to their initial antipsychotic
treatment would enable the consideration of alternative
interventions at an earlier phase of illness to prevent ac-
cruing morbidity. In a well-designed study where a
standardised treatment algorithm was used, only a small
number of patients (23%) responded to a second antipsy-
chotic trial after failing to respond to ﬁrst-line antipsy-
chotics (Agid et al., 2007). However, the majority of
patients (77%) who went on to clozapine after two failed
antipsychotic trials had a robust response. Therefore,
switching to clozapine earlier has been a proposed solu-
tion, as failure to respond to a ﬁrst antipsychotic is highly
predictive of failure to respond to a subsequent antipsy-
chotic, other than clozapine (Remington et al., 2013).
Another reason for investigating treatment non-
response in ﬁrst-episode patients is to further elucidate
the evolution of treatment refractoriness in schizophre-
nia. It has been proposed that most cases of treatment
refractoriness emerge in previously responsive patients
as the illness progresses (Lieberman, 1999). If that is
the case, then the rates of non-response to treatment
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in ﬁrst-episode schizophrenia should be lower than in
multi-episode samples. Poor response to treatment is
common in chronic, multi-episode samples with almost
60% of patients failing to achieve response after
6months on antipsychotic drug therapy (Kennedy
et al., 2014), and up to half are regarded as refractory
to antipsychotic treatment (Conley and Kelly, 2001;
Caspi et al., 2004). In contrast, treatment response in
ﬁrst-episode schizophrenia is frequently favourable
(Robinson et al., 1999). A systematic review calculated
the average rate of poor outcome in ﬁrst-episode sam-
ples as 27%, although rates varied considerably across
studies (Menezes et al., 2006). The inconsistency is
likely due to factors such as differences in criteria ap-
plied to deﬁne non-response, varying study durations,
non-standardisation of treatment and dosage, medica-
tion non-adherence and varying rates of dropout. We
addressed several of these methodological issues by de-
ﬁning an a priori criterion for non-response, treating pa-
tients according to a standard algorithm with a single
antipsychotic, ensuring adherence by way of depot in-
jection and carefully monitoring the cohort to facilitate
study retention. Participants were comprehensively
assessed, which enabled us to explore multiple putative
predictors and clinical concomitants of treatment non-
response. The aims of the study were to estimate the
rate of non-response to ﬁrst-line treatment in ﬁrst-
episode schizophrenia, to evaluate other outcomes as-
sociated with symptom non-response and to identify
demographic, baseline clinical and early treatment re-
sponse predictors of non-response.
METHODS
This was a single-site, longitudinal cohort study
assessing the effects of treatment with ﬂupenthixol
decanoate according to a standardised protocol over
12months in a convenience sample of patients with
ﬁrst-episode schizophrenia. Approval to conduct the
study was obtained from the Human Research Ethics
Committee of Stellenbosch University Faculty of Med-
icine and Health Sciences. The study was conducted in
accordance with the International Conference on Har-
monization guidelines on good clinical practice (Inter-
national Conference on Harmonization, 1996) and was
registered at the South African National Clinical Trials
Register (DOH-27-0710-1957) URL: www.sanctr.
gov.za/SAClinicalTrials/tabid/169/Default.aspx
Participants
Patients were recruited between April 2007 and March
2011 from ﬁrst hospital admissions and community
clinics in the Greater Cape Town area. Patients from
the area are treated at community clinics by psychiatry
residents and community psychiatry nurses. There are
no speciﬁc ﬁrst-episode psychosis/early intervention
services, and it is very difﬁcult to access inpatient ser-
vices. The vast majority of inpatients are admitted as in-
voluntary hospital users, under the Mental Health Care
Act, when they are deemed to be a danger to themselves
or others. Written, informed consent was obtained from
the patients and/or their legal guardians. Inclusion
criteria included men and women, inpatients or outpa-
tients, aged 16–45years, experiencing a ﬁrst psychotic
episode meeting Diagnostic and Statistical Manual of
Mental Diseases, Fourth Edition, Text Revisions
(American Psychiatric Association, 1994a) diagnostic
criteria for schizophrenia, schizophreniform or schizo-
affective disorder, for convenience of reporting referred
to as ﬁrst-episode schizophrenia. Exclusion criteria were
lifetime exposure to >4weeks of antipsychotic medica-
tion, previous treatment with a long-acting depot antipsy-
chotic, serious or unstable general medical condition,
intellectual disability and overt substance abuse.
Treatment
There was a 1-week lead-in period of oral ﬂupenthixol
1–3mg per day followed by long-acting ﬂupenthixol
decanoate injections every 2weeks for the duration of
the study. The starting dose of ﬂupenthixol decanoate
was 10mg 2-weekly, with 6-weekly increments of
10mg permitted, to a maximum of 30mg 2-weekly
or the maximum tolerated dose. The dose was in-
creased at week 6 if patients failed to achieve an ade-
quate response (at least 20% decrease in the total
positive and negative symptom scale score and mini-
mal improvement on the clinical global impression–
improvement (CGI) scale). The dose could be further
increased at week 12 and every 6weeks thereafter if
patients failed to achieve cross-sectional criteria for re-
mission (Andreasen et al., 2005) and a CGI score of
much or very much improved. More rapid upward or
downward titration was permitted if deemed necessary.
A starting dose of 5mg 2-weekly was allowed for pa-
tients aged 18years or younger. Additional oral
ﬂupenthixol tablets were prescribed at the discretion
of the investigator for acute exacerbation of psychotic
symptoms between visits. Investigators were encour-
aged, however, to use lorazepam up to 12mg during
the acute phase and thereafter up to 4mg per day for
agitation. The treatment goal was to achieve symptom
remission. Therefore, for patients with persistent
symptoms, the dose was increased either until remis-
sion was achieved or until the maximum allowed dose
or the maximum tolerated dose was reached.
Flupenthixol decanoate was chosen as it is widely
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available, affordable and remains a popular choice by
psychiatrists in both high-income and low-income set-
tings for treating people with psychosis. Flupenthixol,
belonging to the thioxanthene class, is a high potency
ﬁrst-generation antipsychotic. However, its receptor
binding proﬁle is not dissimilar to several second-
generation antipsychotics, as it antagonises D1-5 dopa-
mine, 5-HT2, H1 histamine and alpha1 adrenergic re-
ceptors (de Wit, 2010). Flupenthixol decanoate has
also been shown to be more cost-effective than long-
acting injectable risperidone (Frey et al., 2014). Per-
mitted concomitant treatment included lorazepam for
sedation, orphenadrine or biperiden for extrapyramidal
symptoms, propranolol for akathisia, antidepressants
for depression and medication for general medical con-
ditions. Prohibited medications included other antipsy-
chotics, mood stabilisers and psychostimulants.
Assessments
Patients were assessed with the Structured Clinical Inter-
view for Diagnostic and Statistical Manual of Mental
Diseases, Fourth Edition (First et al., 1994), the Positive
and Negative Syndrome Scale (PANSS) (Kay et al.,
1987), the Social and Occupational Functioning Assess-
ment Scale (SOFAS) (American Psychiatric Association,
1994b), the Calgary Depression Scale for Schizophrenia
(Addington and Addington, 1993), the Birchwood
Insight Scale (Birchwood et al., 1994), the Premorbid
Adjustment Scale (Cannon-Spoor et al., 1982), the
Neurological Evaluation Scale (NES) (Buchanan and
Heinrichs, 1989), the Extrapyramidal Symptom Rating
Scale (Chouinard and Margolese, 2005), the World
Health Organisation quality of life-BREF scale (The
WHOQOL Group, 1998) and the Measurement and
Treatment Research to ImproveCognition in Schizophrenia
Consensus Cognitive Battery (MCCB) (Green et al., 2004).
Duration of untreated psychosis (DUP) and duration of
untreated illness were estimated, respectively, from the
onset of continuous positive psychotic symptoms and the
onset of ﬁrst recognisable symptoms to the initiation of
treatment. Substance abuse was measured with a structured
substance abuse questionnaire. Furthermore, patients had
urine toxicology for cannabis, methamphetamine and
methaqualone at baseline, 3, 6 and 12months.
Statistical methods
Analyses were performed on all participants who re-
ceived at least one dose of study medication with last
observation carried forward. For differences between
groups, the T-test and the chi-square test were used
to compare continuous and categorical variables, re-
spectively. All tests were two tailed. The signiﬁcance
level was set at 0.05 and not adjusted as these were
considered preliminary analyses to identify the most
suitable predictor variables. To investigate predictors
of non-response, we conducted linear regression, en-
tering demographic, baseline clinical and early
(7weeks) response variables that were selected from
the preliminary analyses together with additional vari-
ables that we considered relevant.
Deﬁning treatment non-response
We aimed to identify all of the participants who experi-
enced prominent persistent symptoms despite an ade-
quate ﬁrst-line antipsychotic treatment trial. Non-
response was deﬁned a priori as any one of the follow-
ing: (i) study discontinuation due to poor response as
judged by the investigator and an assessment panel
consisting of three experienced psychiatrists. All reason-
able measures were taken to keep the patients in the
study and to adhere to the treatment algorithm; (ii) end-
point treatment response <25% in PANSS total score
(recommended minimum response rate for deﬁning re-
fractory patients (Leucht et al., 2009)); or (iii) endpoint
PANSS total score>70. For criteria (ii) and (iii), pa-
tients were only considered to be non-responders if they
had completed at least 3months of treatment and had not
experienced a relapse. We chose a minimum treatment
period of 3months because, although it is well
recognised that antipsychotics act rapidly (Kinon et al.,
2010) and a treatment period of minimum 6weeks has
been proposed (Suzuki et al., 2011), a subset of ﬁrst-
episode patients responds to treatment more slowly
(Emsley et al., 2006b). In keepingwith recommendations
to include a broader range of symptoms when assessing
non-response to treatment (Marder, 1995), we selected
the PANSS total score as the primary measure of
psychopathology rather than selected items or domains.
Early treatment response was calculated as corrected
percentage change in PANSS total score at week 7
(baseline scoreweek 7 score)/(baseline score30). To
assess symptom categories, we calculated scores for the
PANSS factor analysis-derived positive, negative and
disorganised excitement/hostility and depression/anxiety
domains (Emsley et al., 2003). We deﬁned remission ac-
cording to Remission in Schizophrenia Work Group
criteria (Andreasen et al., 2005). Adherence to depot
was calculated as the percentage of actual injections re-
ceived divided by the prescribed number of injections.
RESULTS
The study ﬂow diagram is provided in Figure 1. Of the
126 patients who received at least one dose of study
medication, 85 (67%) patients were recruited from
community clinics, and 41 (33%) were hospitalised at
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the start of the study. Fifteen patients (12%) met our
criteria for non-response. Of the 84 (67%) patients
who completed the study, 61 (48%) achieved remis-
sion, and 23 (18%) improved but did not achieve re-
mission. Thirty (24%) patients dropped out of the
study for reasons other than non-response. The base-
line demographic and clinical characteristics of the
non-responders versus the rest of the sample are pro-
vided in Table 1. Endpoint (last observation carried
forward) values for outcome variables are presented
in Table 2. As anticipated, the non-responders were
characterised by, in addition to higher levels of symp-
tomatology in all domains, poorer functional outcome,
poorer quality of life and greater cognitive impair-
ments. They also had more prominent neurological
soft signs (NSS) and lower body mass index (BMI).
They did not differ from the rest of the cohort in terms
of depression symptoms, levels of insight, extrapyra-
midal symptoms and endpoint ﬂupenthixol dose. How-
ever, they used more benzodiazepines as concomitant
medication. The selected linear regression model in-
cluded the following domains: age, DUP, PANSS
disorganised factor, SOFAS, World Health Organisa-
tion Quality of Life-BREF Scale domains 2 and 3,
NES total, MCCB working memory domain, PANSS
total score change at 7weeks, gender and substance
abuse. The model explained 26% of the variance
(R=0.51; R2=0.26, p=0.01), and NES scores
(p=0.003) and PANSS total score change at 7weeks
(p=0.03) were signiﬁcant independent predictors of
non-response.
In a post-hoc analysis, we applied more stringent
criteria for treatment refractoriness adapted from Suzuki
et al. (2012). According to these criteria, four patients
were classiﬁed as “treatment intolerant” rather than
non-responders, and two patients who discontinued be-
cause of lack of response were excluded because of
not having completed 6weeks of treatment. These
criteria identiﬁed 10 (8%) treatment-refractory patients.
Our window period for the biweekly injections was
3days. Although patients sometimes went beyond this
period, overall adherence was good. One hundred and
twenty-three (98%) patients received 100% of the pre-
scribed depot injections (including patients who
discontinued early), and the other three (2%) patients
received a mean of 61% of the injections.
DISCUSSION
Rate of non-response to ﬁrst antipsychotic treatment
The present study identiﬁed the prevalence of treatment
non-response to ﬁrst antipsychotic treatment in our ﬁrst-
episode schizophrenia cohort as 12%. A study in a ﬁrst-
episode psychosis programme in Canada, which utilised
a treatment algorithm-based approach and measured re-
sponse as a CGI improvement score of much or very
much improved or Brief Psychiatric Rating Scale
thought disorder subscale (conceptual disorganisation,
hallucinatory behaviour, suspiciousness and unusual
thought content) less than 6, found that 24% of ﬁrst-
episode psychosis patients did not respond to the ﬁrst
treatment trial (Agid et al., 2007). However, there may
have been poor adherence and other confounders
inﬂuencing the results. In a recent Nordic outcome study
in ﬁrst-episode psychosis, rates of persistence of psycho-
sis were reported as 16.4% over 2years (Simonsen et al.,
2010). The study was conducted in a naturalistic setting,
and patients were treated with various ﬁrst-generation
and second-generation antipsychotics. Psychosis was
deﬁned broadly and included affective psychosis with
mood-incongruent delusions. Symptom persistence
was deﬁned as a score of 4 or more on at least one of
PANSS items P1, 3, 5, 6 and G9. Mean estimated
reported medication adherence was 76% over the 2-year
study period, suggesting that some patients with
persistent symptoms may have been poorly adherent
rather than non-responsive. In a Canadian naturalistic
study, 15% of ﬁrst-episode patients were found to have
Figure 1. Flow diagram of the study
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Table 1. Comparison of socio-demographic, baseline clinical assessments and early treatment non-response and the rest of the sample
Variable The rest of the sample (n = 111) Non-responders (n = 15) T-value/Chi squared P*
Age (years), mean (SD) 24.5 (6.8) 20.5 (3.7) 2.2 0.026
Sex
Male 82 (74%) 11 (73%) 0.001 0.964
Ethnicity
Mixed 84 (76%) 14 (93%) 2.99 0.233
Black 18 (16%) 0 (0)
White 9 (8%) 1 (7%)
Highest education level
Junior 7 (6%) 2 (13%) 3.88 0.421
Senior 67 (60%) 9 (60%)
Completed Grade 12 24 (22%) 1 (7%)
Tertiary 13 (12%) 3 (20%)
Employment status
Unemployed 88 (79%) 14 (93%) 1.72 0.421
Informal 2 (2%) 0 (0%)
Full time 21 (19%) 1 (7%)
Family history of schizophrenia 42 (38%) 10 (67%) 0.17 0.678
DSM-IV diagnoses
Schizophreniform disorder 34 (31%) 6 (40%) 0.75 0.687
Schizophrenia 75 (68%) 9 (60%)
Schizo-affective 2 (2%) 0 (0%)
Hospitalised at study entry 33 (30%) 8 (53%) 3.35 0.067
Substance abuse 46 (41%) 6 (40%) 0.20 0.654
DUP (weeks), mean (SD) 35.2 (44.7) 28.4 (31.0) 0.6 0.569
DUI (weeks), mean (SD) 81.5 (77.7) 103.6 (123.8) 1.0 0.341
PANSS negative factor, mean (SD) 17.3 (4.7) 19.4 (5.2) 1.6 0.116
PANSS depression anxiety factor, mean (SD) 9.2 (4.3) 9.0 (3.4) 0.2 0.877
PANSS positive factor, mean (SD) 13.5 (2.8) 13.9 (2.5) 0.5 0.607
PANSS excitement/hostility factor, mean (SD) 8.3 (3.8) 10.3 (4.1) 1.9 0.058
PANSS disorganised factor, mean (SD) 17.8 (4.3) 21.4 (4.8) 3.0 0.003
PANSS total score, mean (SD) 93.7 (15.9) 102.7 (19.3) 2.0 0.048
PANSS total change (7 weeks), mean (SD) 0.4 (0.2) 0.3 (0.2) 2.0 0.050
CGI S, mean (SD) 5.0 (0.8) 5.2 (0.6) 1.0 0.310
CDSS total score, mean (SD) 3.3 (4.1) 4.0 (3.9) 0.6 0.528
SOFAS, mean (SD) 44.8 (11.7) 38.1 (8.8) 2.2 0.032
WHOQOL-BREF domain 1, mean (SD) 12.0 (2.4) 11.5 (2.1) 0.8 0.404
WHOQOL-BREF domain 2, mean (SD) 13.2 (2.7) 11.2 (2.7) 2.7 0.009
WHOQOL-BREF domain 3, mean (SD) 12.2 (4.1) 9.4 (4.2) 2.5 0.016
WHOQOL-BREF domain 4, mean (SD) 11.9 (3.3) 10.1 (3.1) 2.0 0.051
NES sensory integration, mean (SD) 2.5 (2.3) 5.3 (2.9) 4.3 0.000
NES motor coordination, mean (SD) 1.2 (1.3) 3.2 (2.4) 5.1 0.000
NES sequencing of motor acts, mean (SD) 2.7 (2.3) 4.9 (2.6) 3.5 0.001
NES total, mean (SD) 13.9 (7.0) 23.6 (9.5) 4.8 0.000
PAS total child, mean (SD) 0.2 (0.2) 0.2 (0.1) 1.4 0.178
PAS total EAdol, mean (SD) 0.3 (0.2) 0.3 (0.2) 0.2 0.806
PAS total LAdol, mean (SD) 0.4 (0.2) 0.3 (0.2) 0.6 0.545
PAS total adult, mean (SD) 0.4 (0.2) 0.4 (0.3) 0.7 0.464
PAS total general, mean (SD) 0.5 (0.2) 0.6 (0.2) 1.7 0.095
PAS overall, mean (SD) 0.4 (0.1) 0.4 (0.1) 0.0 0.960
BIS subscale 1, mean (SD) 2.3 (1.1) 2.2 (0.6) 0.3 0.784
BIS subscale 2, mean (SD) 1.6 (1.3) 1.3 (1.0) 0.9 0.372
BIS subscale 3, mean (SD) 2.2 (1.0) 2.0 (0.9) 0.6 0.548
BIS total, mean (SD) 6.0 (2.1) 5.4 (1.7) 1.0 0.323
ESRS total parkinsonism, mean (SD) 1.7 (3.6) 2.1 (4.7) 0.4 0.684
ESRS total, mean (SD) 2.5 (5.1) 3.9 (8.1) 0.9 0.382
BMI, mean (SD) 21.8 (3.9) 19.8 (3.2) 2.0 0.053
MCCB SOP, mean (SD) 18.2 (16.2) 10.9 (14.2) 1.5 0.130
MCCB AV, mean (SD) 26.3 (11.8) 20.1 (10.1) 1.7 0.097
MCCB WM, mean (SD) 24.5 (915.6) 15.2 (11.7) 2.1 0.042
MCCB Vrbl Lrng, mean (SD) 34.8 (8.6) 31.6 (6.9) 1.3 0.209
MCCB Vis Lrng, mean (SD) 29.9 (15.3) 23.1 (15.1) 1.5 0.134
MCCB RPS, mean (SD) 31.8 (8.7) 32.5 (10.3) 0.3 0.773
MCCB SC, mean (SD) 29.7 (11.8) 23.3 (6.0) 1.8 0.070
MCCB comp score, mean (SD) 14.0 (15.7) 4.5 (9.8) 1.9 0.055
DSM-IV, Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition; SD, standard deviation; MATRICS, measurement and treatment research to improve
cognition in schizophrenia; MCCB, MATRICS consensus cognitive battery; MCCB SOP, MATRICS consensus cognitive battery speed of processing; MCCB AV,
MATRICS consensus cognitive battery attention/vigilance; MCCB WM, MATRICS consensus cognitive battery working memory; MCCB Vrbl Lrng, MATRICS
consensus cognitive battery verbal learning; MCCB Vis Lrng, MATRICS consensus cognitive battery visual learning; MCCB RPS, MATRICS consensus cognitive
battery reasoning and problem solving; MCCB SC, MATRICS consensus cognitive battery social cognition; PANSS, positive and negative syndrome scale; SOFAS,
social and occupational functioning assessment scale; CDSS, Calgary depression scale for schizophrenia; BIS, Birchwood insight scale; PAS, premorbid adjustment
scale; PASEAdol, premorbid adjustment scale early adolescence; PASLAdol, premorbid adjustment scale late adolescence; NES, neurological evaluation scale, ESRS,
extrapyramidal symptom rating scale; WHOQOL-BREF, World Health Organisation quality of life-BREF scale; CGI S, clinical global impression severity scale.
P, signiﬁcance value; T-test, for continuous variables; chi squared, for categorical variables.
Signiﬁcance level was set at 0.05.
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persistent psychosis, deﬁned as a rating of 3 or more on
any subscale of Scale for Assessment of Positive Symp-
toms at baseline, 1 and 2years, and no period of full re-
covery of symptoms at any time during the 2-year period
(Manchanda et al., 2005). In the New York Hillside
Hospital cohort study conducted over 5years (Robinson
et al., 1999), the authors reported an 87% cumulative re-
sponse rate for patients who were moved through a treat-
ment algorithm with various antipsychotics if necessary,
including clozapine. They identiﬁed 10 patients (8% of
the sample) who were refractory to treatment through-
out. Our rate of non-response is more in line with these
three latter studies, suggesting true treatment non-
response rates of between 8% and 16% in ﬁrst-treated
patients with ﬁrst-episode schizophrenia. With more
stringent criteria and in the presence of adequate adher-
ence, the rate of non-response to ﬁrst-line treatment ap-
pears to be less than 10%.
Predictors of non-response
Given the clinical importance of early identiﬁcation of
treatment refractoriness, interest has focused on identify-
ing demographic, clinical and biological predictors of
treatment non-response. While numerous predictors
have been reported, results are inconsistent and strength
of the associations generally weak. Examples of previ-
ously reported predictors include male sex (Robinson
et al., 1999), early age of onset (Meltzer et al., 1997),
positive family history of schizophrenia (Malaspina
et al., 2000), obstetric complications (Alvir et al.,
Table 2. Comparison of endpoint (last observation carried forward) clinical and cognitive scores and study and concomitant medication use between non-
responders and the rest of the sample
Variable The rest of the sample (n = 111) Non-responders (n = 15) T-value or chi square* P
PANSS total, mean (SD) 49 (14.7) 82.6 (12.7) 8.4 <0.0001
PANSS disorganised factor, mean (SD) 6.5 (2.4) 11.4 (2.2) 7.5 <0.0001
PANSS positive factor, mean (SD) 6.6 (4.1) 12.3 (2.5) 5.2 <0.0001
PANSS depression/anxiety factor, mean (SD) 5.4 (2.5) 7.1 (3.6) 2.4 0.02
PANSS negative factor, mean (SD) 11.2 (4.1) 20.8 (5.3) 8.2 <0.0001
PANSS excitement/hostility factor, mean (SD) 5 (2.1) 6.5 (3.2) 2.3 0.02
CGI S, mean (SD) 2.5 (1) 4.3 (0.7) 6.5 <0.0001
CGI improvement, mean (SD) 1.6 (0.8) 2.9 (0.9) 6.0 <0.0001
CDSS total, mean (SD) 1.2 (2.8) 1.9 (2.4) 1.0 0.3
SOFAS, mean (SD) 62.2 (12.8) 46.7 (7.7) 4.6 <0.0001
WHOQOL-BREF domain 1, mean (SD) 12.6 (2.7) 10.9 (2.4) 2.3 0.03
WHOQOL-BREF domain 2, mean (SD) 13.5 (2.5) 11.4 (2) 3.1 0.003
WHOQOL-BREF domain 3, mean (SD) 13.7 (3.8) 11.2 (4.2) 2.4 0.02
WHOQOL-BREF domain 4, mean (SD) 13.7 (3.1) 11.3 (4) 2.8 0.006
NES sensory integration, mean (SD) 1.4 (2) 3.1 (2.7) 2.9 0.004
NES motor co-ordination, mean (SD) 0.8 (1.2) 2.1 (2) 3.9 <0.0001
NES sequencing of motor Acts, mean (SD) 1.6 (1.9) 4.1 (2.9) 4.4 <0.0001
NES total, mean (SD) 9.7 (5.7) 18.3 (8.6) 5.2 <0.0001
BIS 1, mean (SD) 2.1 (1.1) 2.2 (0.6) 0.1 0.9
BIS 2, mean (SD) 1.6 (1.3) 1.4 (1.3) 0.5 0.6
BIS 3, mean (SD) 2.5 (1) 2.6 (0.8) 0.1 0.9
BIS total, mean (SD) 6.2 (2.3) 6.1 (2.1) 0.2 0.9
ESRS change parkinsonism, mean (SD) 1.6 (3.5) 0.3 (2.7) 1.3 0.2
ESRS change total, mean (SD) 2.3 (4.8) 1.1 (3.9) 0.9 0.4
BMI, mean (SD) 24.2 (4.8) 20.5 (3.9) 2.8 0.006
Fluanxol dose, mean (SD) 11.9 (5.4) 10.4 (6.2) 1.0 0.3
Anticholinergics, number (%) 12 (11%) 4 (30%) 3.4 0.07
Antidepressants, number (%) 17 (15%) 1 (7%) 0.7 0.4
Benzodiazepines, number (%) 11 (10%) 4 (30%) 4.0 0.05
Completed week, mean (SD) 38.3 (16.6) 22.2 (17.6) 3.5 0.001
MCCB SOP, mean (SD) 27 (15.3) 13.2 (15.1) 3.1 0.003
MCCB AV, mean (SD) 34.9 (10.9) 24.1 (9.6) 3.3 0.001
MCCB WM, mean (SD) 32.5 (13.3) 20.4 (13.4) 3.1 0.003
MCCB Vrbl Lrng, mean (SD) 37.6 (7.9) 31.9 (3.6) 2.6 0.01
MCCB Vis Lrng, mean (SD) 37.1 (13.3) 27.6 (13.6) 2.4 0.02
MCCB RPS, mean (SD) 37.5 (10.2) 32.8 (10.2) 1.6 0.1
MCCB SC, mean (SD) 33.2 (12.2) 24.8 (12.6) 2.2 0.03
MCCB comp score, mean (SD) 23.4 (14.6) 8.7 (13.2) 3.3 0.001
SD, standard deviation; MATRICS, measurement and treatment research to improve cognition in schizophrenia; MCCB, MATRICS consensus cognitive bat-
tery; MCCB SOP, MATRICS consensus cognitive battery speed of processing; MCCB AV, MATRICS consensus cognitive battery attention/vigilance; MCCB
WM, MATRICS consensus cognitive battery working memory; MCCB Vrbl Lrng, MATRICS consensus cognitive battery verbal learning; MCCB Vis Lrng,
MATRICS consensus cognitive battery visual learning; MCCB RPS, MATRICS consensus cognitive battery reasoning and problem solving; MCCB SC,
MATRICS consensus cognitive battery social cognition; PANSS, positive and negative syndrome scale; SOFAS, social and occupational functioning
assessment scale; CDSS, Calgary depression scale for schizophrenia; BIS, Birchwood insight scale; NES, neurological evaluation scale, ESRS, extrapyramidal
symptom rating scale; WHOQOL-BREF, World Health Organisation quality of life-BREF scale; BMI, body mass index; CGI S, clinical global impression
severity scale.
Signiﬁcance level was set at 0.05
*T-value and chi square for continuous and categorical variable comparisons, respectively.
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1999), longer DUP (Marshall et al., 2005) and tardive
dyskinesia (Lieberman, 1993). In a regression analysis
conducted on results of studies reporting predictors of
poor outcome in ﬁrst-episode samples, the only two fac-
tors predicting poor outcome were treatment with con-
ventional antipsychotics and being treatment naïve at
study entry (Menezes et al., 2006).
In the preliminary analyses, the ﬁndings of poorer
functional outcome, quality of life and cognitive per-
formance in the non-responder group were all antici-
pated, while the lower BMI was unanticipated.
However, the lower BMI could be attributed to ﬁrst,
the younger age of the non-responders, and second,
the shorter duration of exposure to the adipogenic ef-
fects of antipsychotic treatment due to their higher rate
of dropout. Our linear regression model was only able
to explain a relatively small portion of the variance
(26%), indicating that other factors not assessed in
the present study play a role in predicting non-
response. The results replicate a previous study con-
ducted by us in another ﬁrst-episode sample in which
both NSS and early treatment response were identiﬁed
as signiﬁcant predictors of outcome (Emsley et al.,
2006a). The strongest predictor that we identiﬁed in
the present study was prominent NSS. While several
previous studies report no association between NSS
and treatment outcome (Kolakowska et al., 1985;
Sanders et al., 2004; Emsley et al., 2005), an associa-
tion was found between persistence of NSS at 1year
following a ﬁrst episode of schizophrenia and poor
treatment response (Prikryl et al., 2007), and NSS im-
proved to a lesser degree in the early stages of illness
for patients with a poorer outcome (Bachmann et al.,
2005). Also, fewer NSS signiﬁcantly predicted later re-
mission in a ﬁrst-episode sample (Emsley et al.,
2006a).
It is now well recognised that antipsychotic drugs ex-
ert their effects rapidly, with the greatest degree of
symptom reduction occurring within the ﬁrst few weeks
of treatment (Agid et al., 2003). Also, early symptom
improvement is strongly predictive of later treatment re-
sponse (Kinon et al., 2010). However, the majority of
these studies were of short duration, and those that were
of longer duration focused on predicting favourable out-
comes (Emsley et al., 2008). Our results therefore ex-
tend previous ﬁndings by indicating that poor early
treatment response is signiﬁcantly predictive of longer-
term treatment non-response.
Do cases of treatment-emergent refractoriness occur?
It has been proposed that, in addition to its neurodevelop-
mental origins, schizophrenia is a progressive illness and
that in most cases treatment refractoriness develops
during the course of successive episodes (Lieberman,
1999). Arguing against this is that the evidence for dis-
ease progression is not strong and could be explained at
least in part by secondary factors such as substance abuse
and the effects of medication (Zipursky et al., 2013).
Also, in studies assessing treatment outcome in ﬁrst-
episode schizophrenia, no increase in the rates of refrac-
toriness was found in studies of longer duration
(Menezes et al., 2006). On the other hand, there is accu-
mulating evidence to suggest that treatment non-
responsiveness does evolve in some individuals who
previously responded to antipsychotic medication and
that relapse events are critical to its development. Sup-
portive evidence includes the following: (i) Estimates of
refractoriness in multi-episode schizophrenia are consis-
tently higher than in ﬁrst-episode samples—being esti-
mated as between one ﬁfth to one half of patients
(Conley and Kelly, 2001; Caspi et al., 2004)—however,
this ﬁndingmay be explained by selection bias. Multiple-
episode samples may contain more severely ill patients as
they are often recruited from hospital settings. (ii) Some
long-term outcome studies report illness progression re-
lated to relapse events. In a 7-year follow-up study,
80% of patients with schizophrenia had deteriorated over
time, and the degree of deterioration was signiﬁcantly
correlated with the number of relapses that patients expe-
rienced (Curson et al., 1985). In a 15-year follow-up
study in a Dutch incidence cohort, Wiersma et al.
(1998) reported a striking observation—that on average,
one in six patients did not remit after each relapse, irre-
spective of which episode it was. Poor treatment response
increased from 27% after the ﬁrst psychotic episode to
47% after the fourth psychotic episode (Wiersma et al.,
1998). (iii) Studies comparing pre-relapse and post-
relapse treatment response report evidence of emergent
non-responsiveness. A small study comparing treatment
response times of ﬁrst and subsequent episodes reported
that, compared with the ﬁrst episode, the time to remis-
sion was signiﬁcantly longer for the second episode and
third episode (Lieberman et al., 1996); in two studies
comparing treatment response before and after relapse,
one in a ﬁrst episode (Emsley et al., 2013) and the other
in a multi-episode sample (Emsley et al., 2012), evidence
of emergent treatment failure was found in a subset of
16% of the ﬁrst episode and 14% of the multi-episode
samples, respectively. Whether these cases of “emergent
non-responders” differ in any respect from the “inherent
non-responders” remains to be determined.
Other outcome measures associated with
non-response
Our results indicate that ﬁrst-episode patients who fail
to respond to treatment in terms of symptom reduction
non-response in ﬁrst-episode schizophrenia
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also do poorly in several other outcome measures.
Compared with the rest of the sample, they were sig-
niﬁcantly worse in terms of social and occupational
functioning, quality of life and cognitive performance
and had signiﬁcantly higher NES scores. The ﬁnding
that they did not differ regarding insight scores is sur-
prising, given that poor insight has been associated
with poor outcome (Shad et al., 2007). Similarly, the
ﬁnding that non-responders did not differ from the rest
regarding the presence of depressive symptoms is in
contrast to a previous study in which persistent symp-
toms of depression were associated with poor outcome
(Oosthuizen et al., 2006).
Difﬁculties associated with deﬁning treatment
non-response
Accurate identiﬁcation of treatment non-responders is
frequently difﬁcult. Factors such as covert non-
adherence and comorbid disorders need to be carefully
considered. Also, although we did not ﬁnd substance
abuse as a signiﬁcant association of non-response in
our sample, other studies have previously found higher
rates of substance abuse in non-responders (Manchanda
et al., 2005). Furthermore, inconsistencies in criteria ap-
plied to deﬁne non-response, particularly regarding the
degree of symptom reduction and the spectrum of symp-
toms to be included, together with the dose and duration
of what constitutes an adequate trial vary across studies,
making it difﬁcult to compare and interpret the data. Ad-
ditionally, using percentage change in symptoms from
baseline to deﬁne response can be misleading as patients
with higher baseline scores may show considerable per-
centage reduction yet continue to experience prominent
persistent symptoms. This is reﬂected in the ﬁnding that
several of our patients achieved 25% and greater reduc-
tion in PANSS total score yet met our other criteria for
non-response. For this reason, we consider it preferable
to use threshold scores to deﬁne non-response and re-
fractoriness, as is the case with the widely adopted re-
mission criteria developed by the Remission in
Schizophrenia Working Group (Andreasen et al.,
2005). Another difﬁculty in deﬁning non-response in
ﬁrst-episode patients concerns what constitutes an ade-
quate treatment trial. Antipsychotics work rapidly, and
early non-response to antipsychotic treatment is a robust
predictor of subsequent lack of response (Kinon et al.,
2008). Therefore, a 4–6-week period has been regarded
as an adequate trial duration (Kane and Marder, 1993).
However, for ﬁrst-episode patients, a subset appears to
respond more slowly. In a study assessing time to treat-
ment response, response was not achieved until after
4weeks in 22.5% and after 8weeks in 11.2% (Emsley
et al., 2006b). Therefore, a longer treatment trial is
warranted in ﬁrst-episode schizophrenia. Also, the typi-
cal minimum dose requirement of 600mg chlorproma-
zine equivalents per day (Suzuki et al., 2012) may not
be appropriate for ﬁrst-episode patients. Excessive anti-
psychotic doses are not associated with additional thera-
peutic beneﬁt in multi-episode samples, and this may be
particularly the case in ﬁrst-episode samples (Davis and
Chen, 2004). First-episode patients are exquisitely sensi-
tive to the effects of antipsychotic medication and re-
quire lower doses for optimal efﬁcacy (McEvoy et al.,
1991; Oosthuizen et al., 2004). Therefore, a lower min-
imum dose requirement may be appropriate for ﬁrst-
episode patients.
Several limitations need to be considered when
interpreting the ﬁndings of this study. First, as a conve-
nience sample, these patients are not representative of
all ﬁrst-episode schizophrenia patients. Second, it is
possible that some of the patients who dropped out
early for reasons other than non-response could have
been refractory. There were 11 patients who dropped
out for reasons other than non-response before 8weeks.
Similarly, it is possible that some of the early dropouts
due to poor response could have become responders if
they had been able to remain in the study. However,
this is considered unlikely as the decision to discon-
tinue because of poor response was only taken when
the investigators were of the opinion that there was no
realistic chance of improvement. Also, the long-term
outcome of the 15 non-responders that we identiﬁed
is not known and is the subject of an ongoing study. Fi-
nally, it is possible that some patients who discontinued
because of poor tolerability may have responded on a
second-generation antipsychotic. We did not utilise a
crossover design where patients who did not respond
to ﬁrst-line treatment could be switched to a second an-
tipsychotic trial, as we focused on response to ﬁrst-line
antipsychotic treatment where treatment was guaran-
teed my means of a depot antipsychotic. Strengths of
the study include the fact that patients were either treat-
ment naïve or minimally treated—the comprehensive
battery of assessments and the standardised treatment
algorithm. Also, by using depot antipsychotic medica-
tion, we were able to remove the potential confounding
effect of non-adherence.
In conclusion, this study identiﬁed a relatively low
rate, 12%, of non-response to ﬁrst-line antipsychotic
treatment in ﬁrst-episode schizophrenia, which is con-
sistent with the proposal that some cases of treatment
refractoriness emerge during the course of the illness
in individuals who were initially responsive to treat-
ment. Several demographic, baseline clinical and early
treatment response variables may be useful in identify-
ing these non-responders at an early stage of treatment.
b. chiliza ET AL.
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Conclusion 
 
The overall aim of the dissertation was to study the clinical, biological and functional aspects of 
outcome in first episode schizophrenia. We were able to carefully assess, treat and follow up 207 
patients (126 patients from our cohort in Cape Town, South Africa and 81 from Ibadan, Nigeria) with 
first episode schizophrenia over a period of 12 months. To date our study was the largest cohort of 
first-episode schizophrenia patients treated with a long-acting injectable antipsychotic published. 
Therefore, our main contribution to the literature was our ability to comprehensively study the 
outcome of first-episode schizophrenia patients on assured antipsychotic treatment in terms of 
clinical features (response, remission and relapse rates), biological (weight and metabolic changes) 
and functional aspects (social and occupational functioning and quality of life). 
 
Long-acting injectable antipsychotics (LAIs) were developed in the 1960s specifically to address the 
problem of poor adherence in patients with schizophrenia. However, they are most often reserved 
for patients who have proven to be non-adherent or uncooperative, experienced multiple relapses, 
or are treatment refractory (Kane and Garcia-Ribera, 2009).  We believe that LAIs are most useful 
and effective early in the course of schizophrenia (Emsley et al., 2013), because comprehensive 
intervention during the early course of illness is likely to change the long term trajectory and 
outcome of schizophrenia (Birchwood et al., 1998). This early or ‘critical period’, (i.e. the first two to 
five years of the illness), seems to be when the illness is most aggressive and is associated with 
multiple relapses and the greatest loss of functioning (Lieberman et al., 1993). Non- and partial-
adherence to treatment is particularly predominant during the early course of treatment when 
patients are not yet convinced of the need for long-term treatment (Coldham et al., 2002). Yet the 
main predictor of relapse is treatment non-adherence or discontinuation (Robinson et al., 1999). 
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Therefore, multiple relapses and subsequent progression of illness and poorer functioning in the 
early course of illness is most likely due to treatment non-adherence. Consequently, a method of 
ensuring guaranteed antipsychotic delivery (e.g. utilizing LAIs) is ideally suited for first episode 
schizophrenia patients.  
 
Early intervention in resource constrained settings 
Our study was based within the large early intervention in psychosis movement. The early 
intervention wave has spread across many countries in Europe, North America, Australia and Asia 
(McGorry, 2015). However the majority of the early intervention research and services have been in 
upper income countries. There are very few studies that have examined the effects of early 
intervention of first episode schizophrenia in lower and middle income countries (LMICs). One of the 
key principles in early intervention in psychosis is the reduction of duration of untreated psychosis 
(DUP). Since the DUP is one of a few modifiable factors that influence long-term outcome, its 
reduction has been an important target for early intervention work. A recent systematic review 
showed that the DUP is in fact longer in LMICs than in upper income countries (Large et al., 2008). 
Additionally our literature review found that a long DUP is associated with poor outcome in these 
countries. Thus, there is a need to ensure those with first-episode schizophrenia receive psychosis 
treatment early in LMICs to improve long-term outcome. 
 
A recent systematic review which analysed initiatives aimed at reducing DUP found, intensive public 
education and awareness plus changes to the health system to improve pathways to care can 
effectively reduce DUP (Lloyd-Evans et al., 2011). However less intensive intervention initiatives 
failed to reduce DUP due to significant logistical difficulties. Calls for early intervention in LMICs have 
argued that public awareness and education campaigns that target key informants, community 
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health workers, traditional and religious healers may be effective in reducing DUP (Farooq, 2013). 
Indeed, there is now ongoing research to examine whether the collaboration with traditional and 
complementary medicine practitioners will improve patient outcome (Gureje et al., 2015). 
 
The second principle of early intervention is comprehensive treatment of first-episode schizophrenia 
patients after engaging with the services. We believe that in resource constrained settings with 
limited public funding like ours, one should focus on treating first episode schizophrenia patients as 
well as possible in order to improve the long-term outcome. We firmly believe the role for LAIs is 
crucial in treating first-episode schizophrenia patients. Our literature review of remission in LMICs 
showed that first-episode schizophrenia patients had high rates of remission despite a long DUP. 
This is likely due to the fact that some of the studies included in the review utilized LAIs for treating 
patients. Our study proved an older cost-effective antipsychotic, flupenthixol decanoate, can 
remarkably increase rates of remission, which gives further evidence for the utilization of LAIs in first 
episode schizophrenia within resource constrained settings. 
 
Efficacy of a long-acting injectable antipsychotic 
The majority of patients with first-episode schizophrenia have a robust response to antipsychotic 
treatment, unlike multi-episode patients (Robinson et al., 1999). However the response is typically 
not sustained for a sufficient duration to produce symptomatic remission. Our study found that by 
combining flupenthixol decanoate with a simple assertive monitoring programme, 82% of our 
patients responded to treatment, while 60% were able to meet the remission criteria by the end of 
the study. The rate of remission of our study is indeed remarkable as other studies have found lower 
remission rates (e.g. the large EUFEST study found remission rates varied from 17 – 41%) (Boter et 
al., 2009). Other studies where patients were treated within comprehensive early intervention 
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services also found low remission rates (e.g. Addington and Addington, 2008). Interestingly, in an 
earlier study from our research group, very similar rates of remission (64%) were found in a smaller 
cohort of first episode schizophrenia patients treated with long-acting injectable risperidone (Emsley 
et al., 2008). It is important to note, in our resource constrained setting, that flupenthixol decanoate 
has been found to be more cost-effective than long-acting injectable risperidone (Frey et al., 2014).  
 
Our results support our view that long-acting injectable antipsychotics should be used as first line 
treatment in first-episode schizophrenia in order to improve patient outcome. Symptomatic 
remission has been associated with improved functioning and better quality of life. Therefore, we 
believe the continuous sustained delivery of an antipsychotic allowed the majority of our patients to 
achieve remission, thereby setting the stage for improved long-term outcome and even recovery. 
 
Tolerability of a long-acting injectable antipsychotic  
Since flupenthixol decanoate belongs to the first-generation class of antipsychotics, we were 
concerned that extrapyramidal effects would be one of the most significant side effects in our 
patients. We thus opted for a low-dose strategy as patients with first-episode schizophrenia are 
particularly sensitive to the side effects of antipsychotics (McEvoy et al., 1991). We found mild rates 
of extrapyramidal effects which were present in only a third of our cohort. The majority of the 
extrapyramidal effects were easily treated with anticholinergics or propranolol. Only 3% of our 
patients developed transient dyskinesia over the period of the study. We concluded that the low 
rates of extrapyramidal effects were due to the use of low dose of antipsychotics. With LAIs 
clinicians are able to titrate the dose of the medication such that minimum effective dosing is used. 
However the use of low doses of haloperidol in a previous study from our group did not protect 
patients from developing tardive dyskinesia (Oosthuizen et al., 2003). The second possible reason for 
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the low rates of extrapyramidal effects may be related to the improved pharmacokinetic properties 
of LAIs. The plasma concentrations of the medication are more consistent and more likely to stay 
within the effective plasma range. Oral medications often have more varied plasma concentrations 
related to administration timing and food effects, such that side effects associated with peak plasma 
levels are more common than with LAIs. 
 
The extent of the weight and metabolic changes were however surprising. Our cohort gained 
considerable weight over 12 months of treatment. Weight gain was significant early on (at 6 weeks) 
and continued throughout the study. We know first-episode schizophrenia patients are sensitive to 
potential weight gain while taking antipsychotics (Alvarez-Jimenez et al., 2008), however the focus of 
most published studies has been on second generation antipsychotics. Flupenthixol has been 
characterised as being weight neutral among chronic schizophrenia samples, therefore the 
substantial mean weight gain was unexpected. There was a subset of patients (23%) who gained 
severe weight gain (measured as > 14% of body of weight), at 12 weeks. These patients could prove 
interesting for future pharmacogenomic predictor of weight gain studies, but also for clinicians who 
should place more clinical attention on these patients. Our future research will focus on these 
patients in order to determine if early severe weight gain could be predictive of later weight and 
metabolic changes, since we found no clinically meaningful predictors of weight gain.  
 
Accompanying the weight and BMI changes, our cohort had significant changes in their lipid profiles. 
The increases in triglycerides (TG) and reductions in high density lipoproteins (HDL) gave rise to 
highly significant increases in the TG/HDL ratio. This is of particular concern as this ratio is an 
atherogenic marker and a predictor of cardiovascular disease. Our finding of an increase in the 
number of risk factors for metabolic syndrome is of further concern. Our study was able to 
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convincingly demonstrate the magnitude of the problem because the majority of our patients were 
fully adherent to treatment and completed the study. Interestingly, we did not find a significant 
increase in fasting blood glucose and there was no correlation between changes in BMI and 
metabolic markers, other than TG. These findings raise further questions for future studies 
particularly around the mechanisms of weight and metabolic changes. Future studies should also 
focus on interventions that ameliorate weight and metabolic changes, such as focusing on diet and 
lifestyle changes, exercise and smoking cessation. 
 
Initial treatment refractoriness 
The evolution of treatment refractoriness is poorly understood. Whilst some patients are non-
responsive from the outset, others appear to respond initially and only develop refractoriness 
following a relapse (Emsley et al., 2013). Actual rates of true refractoriness are not known, as in 
many cases the persistence of positive symptoms could be due to non- or partial adherence to 
antipsychotic medication. The only way to control for the confounding effect of non- or partial 
compliance is to ensure antipsychotic medication is delivered by means of a long-acting injection. 
 
 Our study was able to carefully assess true rates of non-response to first line antipsychotic 
treatment. We found very low rates of non-response to treatment (12%), and it appears that these 
were patients were non-responders from the outset. These patients were more likely to have 
prominent neurological soft signs and showed poor early treatment response. Treatment non-
responders are an important group of patients to identify early in order to avoid accruing morbidity 
and unnecessary treatment trials (Agid et al., 2007). Patients who failed to respond to a first line 
antipsychotic are also unlikely to respond to another antipsychotic. Therefore early use of clozapine 
in these patients has been recommended as early effective treatment and is associated with better 
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outcome (Remington et al., 2013). Future research should test this strategy by comparing patients 
with prominent neurological soft signs and poor early response to first line antipsychotics, who are 
later switched to clozapine and compared to those who stay on another non-clozapine 
antipsychotic. 
 
Future research direction 
Our research team plans to examine the effectiveness of the combination of LAI plus assertive 
monitoring program. This is best demonstrated by utilising a pragmatic cluster randomized trial 
where different community clinics are randomized to LAI management of first episode schizophrenia 
patients plus an assertive monitoring program or treatment as usual. This research design will not 
only ascertain whether our treatment strategy is effective when implemented within routine care, 
but also determine how to scale up the intervention. The simple assertive monitoring program is 
straightforward and can be delivered by primary health care providers, thus ideal for resource 
constrained settings. In order to have a broader impact on public health, these research findings 
should be disseminated to government to influence policy and treatment guidelines. 
 
Our research team also plans to embark on a long-term follow up of this cohort of first-episode 
schizophrenia patients to assess whether our intervention during the critical period of treatment had 
any effects on long-term outcome. We will examine the course of illness, remission and recovery 
rates as well as functional aspects of outcome, including quality of life and social and occupational 
functioning. We shall also further examine the evolution of treatment refractoriness and long-term 
weight and metabolic features. We believe that this very carefully assessed and treated cohort will 
be able to give us a wealth of information on the early course of treatment as other recently 
published studies (e.g. Morgan et al., 2014). This long-term follow up will indeed give further 
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evidence as to whether early effective management of first-episode schizophrenia patients with 
assured antipsychotic delivery during the critical period influences long-term outcome. 
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